<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00471237</url>
  </required_header>
  <id_info>
    <org_study_id>CR9108963</org_study_id>
    <nct_id>NCT00471237</nct_id>
  </id_info>
  <brief_title>A Phase II Study Evaluating SB-751689 in Post-Menopausal Women With Osteoporosis.</brief_title>
  <official_title>Study CR9108963: A 12-month, Randomized, Double-blind, Parallel-group, Placebo and Active-controlled Dose-range Finding Study of the Efficacy and Safety of SB-751689 in Post-menopausal Women With Osteoporosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 12 month study designed to evaluate the safety and effectiveness of SB-751689 in
      the treatment of osteoporosis in post-menopausal women, in comparison with 2 active
      comparators and placebo.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Terminated for futility by sponsor after a pre-planned interim review of data
  </why_stopped>
  <start_date type="Actual">May 14, 2007</start_date>
  <completion_date type="Actual">December 26, 2008</completion_date>
  <primary_completion_date type="Actual">December 26, 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change From Baseline in Bone Marrow Density (BMD) at Month 12 Measured by Dual-Energy X-Ray Absorptiometry (DXA) Scans of the Lumbar Spine (L1-L4)</measure>
    <time_frame>Baseline (Day 0) and 12 Months</time_frame>
    <description>DXA scanners from Hologic and GE Lunar was used to measure BMD by a DXA scan. At least two vertebrae (L1-L4) that were suitable for measurement of BMD were evaluated. The same scanner was used throughout the study for all measurements for a given participant. DXA scans were sent to a central reading facility for quality control and central analysis. Assessments performed on Day 0 were considered as Baseline. Percent change from Baseline was computed as (change from baseline / baseline value) * 100%. Percent change from Baseline in areal bone mineral density (aBMD) was reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Hypercalcemia</measure>
    <time_frame>Up to Month 12</time_frame>
    <description>Participants with albumin-adjusted serum calcium pre-dose values of &gt;11.0 mg/ deciliter (dL) or post-dose values of &gt;12.0 mg/dL were recorded as participants with hypercalcemia. Number of participant with hypercalcemia were reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Withdrew Due to Hypercalcemia</measure>
    <time_frame>Up to Month 12</time_frame>
    <description>A confirmed albumin-adjusted serum calcium pre-dose value of &gt;11.0 mg/dL or post-dose value of &gt;12.0 mg/dL was set as a withdrawal criteria for the study. Number of participants who met this pre-defined stopping criteria were reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participant With Laboratory Abnormalities of Potential Clinical Concern at Any Post-baseline Visit</measure>
    <time_frame>Up to Month 12</time_frame>
    <description>The hematology parameters analyzed were white blood cells (WBC) count with differential WBC count, red blood cells, haemoglobin, haematocrit, mean corpuscular volume and platelet count. The clinical chemistry parameters analyzed were sodium, potassium, calcium, calcium (albumin adjusted), phosphate, bicarbonate, creatinine, bilirubin (total), alanine amino transferase, aspartate amino transferase, glucose, albumin, alkaline phosphatase, creatine phosphokinase, urea, uric acid, total protein, 25-OH vitamin D, 1,25-2(OH) vitamin D, whole parathyroid hormone (PTH 1-84)) and intact PTH (1-84 and 7-84). Only those parameters for which at least one value of potential clinical importance was reported are summarized. The number of participants with potential clinical important laboratory findings at any visit were reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participant With Vital Signs of Potential Clinical Concern at Any Post-baseline Visit</measure>
    <time_frame>Up to 12 Months</time_frame>
    <description>The potential clinical importance ranges (low and high) of the vital sign parameters-systolic blood pressure (&gt; 30 millimeter of mercury [mmHg] decrease from Baseline, &gt; 30 mmHg increase from Baseline), diastolic blood pressure (&gt; 20 mmHg decrease from Baseline and &gt; 20 mmHg increase from Baseline) and heart rate (&lt;45 and &gt;120 beats per minute). Only those parameters for which at least one value of potential clinical importance was reported are summarized. The number of participants with potential clinical important vital parameter findings at any visit were reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participant With Electrocardiogram (ECG) Findings Reported as Adverse Event</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Full 12-lead ECGs pre-dose at screening and visits 6, 8, 11, 12 and 14 were recorded. Participants rested supine or seated for at least 10 minutes before each reading. All ECGs were transmitted to a central reviewer for blinded assessment. The central reviewer measured the following parameters and provide a clinical interpretation: heart rate, RR interval, PR interval, QRS interval, QT (uncorrected) interval, QTcB (Bazett's correction) interval, QTcF (Fridericia's correction) interval. The central reviewer was provided the investigator or designated qualified site physician with a central ECG report or confirmatory report to assist them in identifying any clinically significant abnormalities that would preclude the participant from further participation in the study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Change From Baseline in Height</measure>
    <time_frame>Baseline (Day 0), Month 6, 12 and early withdrawal</time_frame>
    <description>Assessments performed on Day 0 were considered as Baseline. Change from Baseline was computed as values at post baseline visit minus Baseline value. Mean change from baseline in height at Month 6 and 12 and early withdrawal were reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Change From Baseline in Weight</measure>
    <time_frame>Baseline (Day 0), Month 6, 12 and early withdrawal</time_frame>
    <description>Baseline values were assessed on Day 0. Change from Baseline was computed as values at post baseline visit minus Baseline value. Mean change from baseline in weight at Month 6, 12 and early withdrawal were reported.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Month 6 in BMD Measured by DXA Scans of the Lumbar Spine (L1-L4)</measure>
    <time_frame>Baseline (Day 0) and Month 6</time_frame>
    <description>DXA scanners from Hologic and GE Lunar was used to measure BMD by a DXA scan. At least two vertebrae (L1-L4) that were suitable for measurement of BMD were evaluated. The same scanner was used throughout the study for all measurements for a given participant. DXA scans were sent to a central reading facility for quality control and central analysis. Baseline values were assessed on Day 0. Percent Change from Baseline was computed as (change from baseline / baseline value) * 100%. Percent change from baseline to month 6 in aBMD was reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Months 6 and 12 in BMD Measured by DXA Scans of the Hip (Total Hip, Femoral Neck and Trochanter).</measure>
    <time_frame>Baseline (Day 0), Month 6 and Month 12</time_frame>
    <description>DXA scanners from Hologic and GE Lunar was used to measure BMD by a DXA scan. At least two vertebrae (L1-L4) that were suitable for measurement of BMD were evaluated. The same scanner was used throughout the study for all measurements for a given participant. DXA scans were sent to a central reading facility for quality control and central analysis. Baseline values were assessed on Day 0. Percent Change from Baseline was computed as (change from baseline / baseline value) * 100%. Percent change from baseline to month 6 and 12 in aBMD of hip (total hip, femoral neck and trochanter) were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Remained the Same or Had Any Improvement in DXA BMD (&gt; Baseline)</measure>
    <time_frame>Baseline (Day 0), Month 5, 6 and 12</time_frame>
    <description>Responder rate of participants who remained the same or had any improvement as compared to baseline in DXA BMD of vertebra, femur and vertebra plus femur were reported. Baseline values were assessed on Day 0. Percent change (improvement) from Baseline was computed as (change from baseline / baseline value) * 100%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Month 12 in the Volumetric Integral, Cortical, and Trabecular Density (BMD) at the Hip and Lumbar Spine as Measured by Quantitative Computer Tomography (QCT) Scans</measure>
    <time_frame>Baseline (Day 0) and Month 12</time_frame>
    <description>QCT is a three-dimensional non-projectional technique to quantify BMD with a number of advantages to other densitometric techniques. Cortical and trabecular bone can be separated, trabecular volume of interest (VOI) are largely independent of degenerative changes in the spine and 3 dimensional geometric parameters can be determined. BMD as measured by QCT is a true density measured in g/cm^3 in contrast to DXA Which determines an areal density measured in g/cm^2. Baseline values were assessed on Day 0. Percent change from Baseline was computed as (change from baseline / baseline value) * 100%. Percent change from Baseline to month 12 in the volumetric integral, cortical, and trabecular density (BMD) at the hip and lumbar spine measured by QCT were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Month 12 in the Total Vertebra Integral VOI at the Lumbar Spine as Measured by QCT Scans</measure>
    <time_frame>Baseline (Day 0) and Month 12</time_frame>
    <description>QCT is a three-dimensional non-projectional technique to quantify BMD with a number of advantages to other densitometric techniques. Cortical and trabecular bone can be separated, trabecular VOI are largely independent of degenerative changes in the spine and 3 dimensional geometric parameters can be determined. BMD as measured by QCT is a true density measured in g/cm^3 in contrast to DXA Which determines an areal density measured in g/cm^2. Baseline values were assessed on Day 0. Percent change from Baseline was computed as (change from baseline / baseline value) * 100%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Month 12 in the Volumetric Integral, Cortical, and Trabecular Density (BMD) at the Hip as Measured by QCT Scans</measure>
    <time_frame>Baseline (Day 0) and Month 12</time_frame>
    <description>QCT is a three-dimensional non-projectional technique to quantify BMD with a number of advantages to other densitometric techniques. Cortical and trabecular bone can be separated, trabecular VOI are largely independent of degenerative changes in the spine and 3 dimensional geometric parameters can be determined. BMD as measured by QCT is a true density measured in mg/cm^3 in contrast to DXA Which determines an areal density measured in g/cm^2. Baseline values were assessed on Day 0. Percent change from Baseline was computed as (change from baseline / baseline value) * 100%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to Month 12 in Cortical Thickness at the Hip as Measured by QCT Scans</measure>
    <time_frame>Baseline (Day 0) and Month 12</time_frame>
    <description>Percent change in thickness of femur neck cortical VOI thickness and trochanter cortical VOI thickness were at Month 12 measured by QCT were reported. Assessments performed on Day 0 were considered as Baseline. Percent change from Baseline was computed as (change from baseline / baseline value) * 100%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemical Markers of Bone Turnover: Levels of C-terminal Telopeptide α1 Chain of Type 1 Collagen (CTX1)</measure>
    <time_frame>Baseline (Day 0), Week 4, Month 3, 6, and 12</time_frame>
    <description>Blood samples were collected at Baseline (Day 0), Week 4, Month 3, 6, and 12 for measurement of CTX1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemical Markers of Bone Turnover: Procollagen Type 1 N-terminal Propeptide (P1NP)</measure>
    <time_frame>Baseline (Day 0), Week 4, Month 3, 6, and 12</time_frame>
    <description>Blood samples were collected at Baseline (Day 0), Week 4, Month 3, 6, and 12 for measurement of P1NP.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemical Markers of Bone Turnover: Bone Specific Alkaline Phosphatase (BALP)</measure>
    <time_frame>Baseline (Day 0), Week 4, Month 3, 6, and 12</time_frame>
    <description>Blood samples were collected at Baseline (Day 0), Week 4, Month 3, 6, and 12 for measurement of BALP.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Concentrations of Ronacaleret</measure>
    <time_frame>Pre-dose (0.0 hour [h]) and 12 h post dose at Week 4, 20, 40 min, 1, 1.5, 2.0, 2.5, 3.0, 4.0, 6.0, 8.0, 1-4, 8-12, and 24 h at Month 3, 6 and 12</time_frame>
    <description>Blood samples were collected and analyzed for concentrations of ronacaleret. The individual blood concentration-time data from the intensive PK-PD subgroup of participants were analyzed by standard noncompartmental methods. Blood concentrations of ronacaleret were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration-time Curve Over the Dosing Interval (AUC 0-t) and Area Under the Concentration-time Curve Over the Dosing Interval (AUC 0-tau) of Ronacaleret</measure>
    <time_frame>Pre-dose (0.0 h) and 12 h post dose at Week 4, 20, 40 min, 1, 1.5, 2.0, 2.5, 3.0, 4.0, 6.0, 8.0, 1-4, 8-12, and 24 h at Month 3, 6 and 12</time_frame>
    <description>Blood samples were collected and analyzed for concentrations of ronacaleret. The individual blood concentration-time data from the intensive pharmacokinetic and pharmacodynamics subgroup of participants were analyzed by standard noncompartmental methods. Blood samples were collected and analyzed for concentrations of ronacaleret. The individual blood concentration-time data from the intensive PK-PD subgroup of participants were analyzed by standard noncompartmental methods. Following log transformation, AUC(0-t) and AUC(0-τ) of ronacaleret were separately analyzed by ANOVA using mixed effects model, fitting treatment and country/region as fixed effects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Blood Concentration (Cmax) of Ronacaleret</measure>
    <time_frame>Pre-dose (0.0 h) and 12 h post dose at Week 4, 20, 40 min, 1, 1.5, 2.0, 2.5, 3.0, 4.0, 6.0, 8.0, 1-4, 8-12, and 24 h at Month 3, 6 and 12</time_frame>
    <description>Blood samples were collected and analyzed for concentrations of ronacaleret. The individual blood concentration-time data from the intensive pharmacokinetic and pharmacodynamics subgroup of participants were analyzed by standard noncompartmental methods. Blood samples were collected and analyzed for concentrations of ronacaleret. The individual blood concentration-time data from the intensive PK-PD subgroup of participants were analyzed by standard noncompartmental methods. Following log transformation, Cmax of ronacaleret were separately analyzed by ANOVA using mixed effects model, fitting treatment and country/region as fixed effects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time Required to Achieve Maximum Concentration of Ronacaleret in Blood (Tmax)</measure>
    <time_frame>Pre-dose (0.0 h) and 12 h post dose at Week 4, 20, 40 min, 1, 1.5, 2.0, 2.5, 3.0, 4.0, 6.0, 8.0, 1-4, 8-12, and 24 h at Month 3, 6 and 12</time_frame>
    <description>Blood samples were collected and analyzed for concentrations of ronacaleret. The individual blood concentration-time data from the intensive pharmacokinetic and pharmacodynamics subgroup of participants were analyzed by standard noncompartmental methods.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">564</enrollment>
  <condition>Osteoporosis</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>All subjects will take calcium (500-660mg elemental daily) and vitamin D (at least 400IU daily) supplements once daily in the evening throughout the study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Alendronate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>All subjects will take calcium (500-660mg elemental daily) and vitamin D (at least 400IU daily) supplements once daily in the evening throughout the study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Teriparatide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Open-label arm. All subjects will take calcium (500-660mg elemental daily) and vitamin D (at least 400IU daily) supplements once daily in the evening throughout the study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ronacaleret</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 arms, 100mg, 200mg, 300mg, 400mg. All subjects will take calcium (500-660mg elemental daily) and vitamin D (at least 400IU daily) supplements once daily in the evening throughout the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ronacaleret</intervention_name>
    <description>100mg, 200mg, 300mg, 400mg</description>
    <arm_group_label>Ronacaleret</arm_group_label>
    <other_name>SB-751689</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Teriparatide</intervention_name>
    <description>PTH (1-34)</description>
    <arm_group_label>Teriparatide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alendronate</intervention_name>
    <description>Bisphosphonate</description>
    <arm_group_label>Alendronate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion:

          -  Informed consent: Subject is willing and able to provide written informed consent.

          -  Menopausal status: Ambulatory female aged &lt; 80 years at screening and &gt;5 years
             postmenopausal.

          -  T-Score: A subject with either no or only one prevalent vertebral fracture is eligible
             for inclusion if she satisfies one of the following T-score requirements:

        If no prevalent vertebral fracture subject must have an absolute BMD value consistent with
        a T-score of less than or equal to -2.5 and greater than -4.0 at either the femoral neck,
        total hip, trochanter, or lumbar spine, or If one prevalent vertebral fracture subject must
        have an absolute BMD value consistent with a T-score of less than or equal to -2.0 and
        greater than -4.0 at either the femoral neck, total hip, trochanter, or lumbar spine.

          -  Suitable vertebra: Two or more vertebra in the range of L1 to L4 that are suitable for
             BMD measurement by DXA.

          -  Protocol compliance: Subject who, in the opinion of the investigator, is willing and
             able to comply with the requirements of the protocol.

        Exclusion:

          -  T-Score: Has an absolute BMD value consistent with a T-score less than or equal to
             -4.0 at either the femoral neck, total hip, trochanter, or lumbar spine.

          -  Vertebral fractures: Has &gt;1 prevalent vertebral fracture at the screening visit.

          -  Non-vertebral fractures: Any previous non-vertebral osteoporosis related/fragility
             fracture after age 40.

          -  Spine deformity: Significant spine deformity which would preclude DXA/QCT assessments.

          -  BMI: BMI ≥33kg/m2.

          -  Bone metabolic diseases: Other than osteoporosis, history or concurrent diseases
             affecting bone metabolism (e.g., osteomalacia, hyperparathyroidism, hyperthyroidism).

          -  GI disease: History of major upper gastrointestinal disease

          -  Malabsorption: Active or history of malabsorption (e.g., history of celiac disease,
             irritable bowel syndrome or inflammatory bowel disease).

          -  Liver disease: Past or current history of liver disease or known hepatic or biliary
             abnormalities, (with the exception of previously documented diagnosis of Gilbert's
             syndrome).

          -  Rheumatoid arthritis: Active disease or history of rheumatoid arthritis.

          -  Nephrolithiasis: History of or active nephrolithiasis (kidney stones).

          -  Osteosarcoma risk: Subjects at increased risk of osteosarcoma such as those with
             Paget's disease of bone or any prior external beam or implant radiation therapy
             involving the skeleton.

          -  Malignancy: Malignant disease diagnosed within the previous 5 years (except resected
             basal cell cancer).

          -  Biological abnormalities: Any clinically relevant biological abnormality found and/or
             volunteered at screening (other than those related to the disease under investigation)
             which, in the opinion of the investigator, is clinically significant and would
             preclude safe participation in this study.

          -  Surgical and medical conditions: Presence of the following conditions within six
             months prior to screening: myocardial infarction, coronary bypass surgery, coronary
             artery angioplasty, unstable angina, cardiac arrhythmia, clinically evident congestive
             heart failure, or cerebrovascular accident.

          -  Glomerular filtration rate: Glomerular filtration rate (GFR) &lt;35 mL/min as calculated
             by the Modification of Diet in Renal Disease (MDRD) equation as follows: GFR
             (mL/min/1.73 m2) = 186 x (Serum creatinine mg/dL)-1.154 x (Age)-0.203 x (0.742 if
             female) x (1.210 if African American) (conventional units).

          -  QT/QTc prolongation: A marked baseline prolongation of QT/QTc interval (e.g., QTc
             interval ≥450 msec on the Screening ECG).

          -  Torsades de Pointes: A history of risk factors for Torsades de Pointes (e.g., heart
             failure, hypokalemia, family history of Long QT Syndrome).

          -  Liver chemistries: Liver chemistries [aspartate aminotransferase (AST), alanine
             aminotransferase (ALT) or total bilirubin] exceeding 2-fold the upper limit of the
             laboratory-specified reference range, at screening.

          -  Abnormal serum calcium: Serum calcium (total or albumin-adjusted) outside the central
             laboratory reference range at the screening visit.

          -  Abnormal PTH: PTH (intact or whole) outside the normal range.

          -  Abnormal creatine phosphokinase: Creatine phosphokinase (CPK) outside the normal
             range.

          -  Abnormal alkaline phosphatase: Alkaline phosphatase outside of the normal range.

          -  Thyroid hormone replacement: Subjects receiving thyroid hormone replacement therapy
             must have a TSH level checked. Subjects will be excluded if TSH levels are &lt;0.1 or
             &gt;10.0mIU/L. However, subjects will not be excluded if TSH is in the range 0.1-4.5
             mIU/L. If TSH is &gt;4.5 and ≤10.0mIU/mL, measure T4 and exclude the subject only if the
             T4 is outside the normal range.

          -  Vitamin D deficiency: Vitamin D deficiency (serum 25-hydroxy vitamin D &lt; 20ng/mL,
             equivalent to 50nmol/L) at screening. Subjects can undergo vitamin D repletion as per
             local practice and be re-screened once only for vitamin D levels within the 6-week
             screening period. They will remain excluded if the re-screened value is &lt; 20ng/mL.

          -  Previous strontium or IV bisphosphonate: Any previous treatment with strontium
             ranelate or intravenous bisphosphonate.

          -  Oral bisphosphonates: Any previous treatment with an oral bisphosphonate as follows:

        any treatment within the last six months

          -  one month cumulative treatment within the last 12 months

          -  three months cumulative treatment within the past two years, or

          -  two years cumulative treatment within the past five years.

               -  Fluoride: Treatment with fluoride (dose greater than 10mg/day) within the
                  previous 5 years for osteoporosis.

               -  Digoxin: Current therapy with digoxin.

               -  Bone metabolism drugs: Treatment with other drugs affecting bone metabolism
                  within the last six months prior to screening:

        Chronic systemic corticosteroid [e.g., glucocorticoid, mineralocorticoid] treatment of no
        more than 2 intra-articular injections within the past year or use of oral, parenteral, or
        long-term, high-dose inhaled corticosteroids. Treatment with any topical corticosteroid
        will not exclude the subject from participating.

        Hormones [e.g., estrogens/&quot;natural estrogen preparations&quot;(except for nonsystemic vaginal
        treatment), 19-norprogestins, SERMs such as raloxifene, anabolic steroids/androgens such as
        dehydroepiandrosterone (DHEA) or its sulfated form (DHEAS), nandrolone, tibolone, active
        vitamin D analogs/metabolites such as 1,25-dihydroxy vitamin D (calcitriol) or
        1alpha-hydroxyvitamin D3 (1-alpha hydroxycholecalciferol), calcitonin].

        Calcineurin inhibitors [e.g., cyclosporine, tacrolimus] or methotrexate.

          -  Previous anabolic agents: Treatment with PTH, PTH analogues or similar anabolic agent
             for osteoporosis within the last two years.

          -  Contraindications: Contraindications to therapy with calcium or vitamin D.

          -  Pregnancy: Women who are pregnant are not allowed in this study.

          -  Interfering medications: Vitamin A in excess of 10,000 IU per day, heparin, or
             lithium, or anticonvulsant medications except benzodiazepines.

          -  Investigational drug exposure: Administration of any investigational drug within 90
             days preceding the first dose of the study drug.

          -  Substance abuse: History or current evidence of drug or alcohol abuse within the
             previous 12 months.

          -  Problems swallowing: Inability to swallow a tablet whole.

        The following exclusion criteria do not apply to subjects allocated to the open-label
        teriparatide group:

          -  Calcium channel blockers: Current therapy with calcium channel blockers diltiazem and
             verapamil.

          -  Oral Azole Antifungals: Current therapy with any oral azole antifungal.

          -  Immunosuppressants: Current therapy with cyclosporine or oral tacrolimus.

          -  Ritonavir: Current therapy with ritonavir.

          -  Quinidine: Current therapy with quinidine.

          -  Macrolide Antibiotics: Subjects anticipated to require chronic use of macrolide
             antibiotics.

          -  Alendronate Contraindications: Contraindications to therapy with alendronate.
             Additional Exclusion Criteria for Subjects Recruited at QCT Sites

          -  Hip surgery: History of hip surgery resulting in a metal implant on either the left or
             right side that would cause an artefact on a QCT scan.

        Additional Exclusion Criteria for Teriparatide Subjects

          -  Teriparatide contraindications: Contraindications to therapy with teriparatide
             according to locally approved datasheet.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Palm Desert</city>
        <state>California</state>
        <zip>92260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>94598</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44313</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <zip>16635</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ciudad Autónoma de Buenos Aires</city>
        <state>Buenos Aires</state>
        <zip>C1117ABH</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ciudad Autonoma de Buenos Aires</city>
        <zip>1012</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ciudad Autónoma de Buenos Aires</city>
        <zip>C1128AAF</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>St Leonards</city>
        <state>New South Wales</state>
        <zip>2065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Footscray</city>
        <state>Victoria</state>
        <zip>3011</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Geelong</city>
        <state>Victoria</state>
        <zip>3220</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Heidelberg</city>
        <state>Victoria</state>
        <zip>3081</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Liege</city>
        <zip>4020</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tienen</city>
        <zip>3300</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ballerup</city>
        <zip>2750</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Frankfurt</city>
        <state>Hessen</state>
        <zip>60528</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>10559</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>12203</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>12247</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>13125</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <zip>22143</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <zip>22415</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Shatin</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Suwon</city>
        <zip>443-721</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mexico, D.F.</city>
        <zip>14050</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bergen</city>
        <zip>5094</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hamar</city>
        <zip>2317</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Oslo</city>
        <zip>0176</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Grudziadz</city>
        <zip>86-300</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Warszawa</city>
        <zip>02-341</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-088</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Moscow</city>
        <zip>117292</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Moscow</city>
        <zip>127299</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Panorama</city>
        <zip>7500</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rosebank</city>
        <zip>2196</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Somerset West</city>
        <zip>7130</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08022</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Santiago de Compostela</city>
        <zip>15705</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Santiago de Compostela</city>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Hong Kong</country>
    <country>Korea, Republic of</country>
    <country>Mexico</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <reference>
    <citation>Fitzpatrick LA, Dabrowski CE, Cicconetti G, Gordon DN, Fuerst T, Engelke K, Genant HK. Ronacaleret, a calcium-sensing receptor antagonist, increases trabecular but not cortical bone in postmenopausal women. J Bone Miner Res. 2012 Feb;27(2):255-62. doi: 10.1002/jbmr.554.</citation>
    <PMID>22052452</PMID>
  </reference>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 7, 2007</study_first_submitted>
  <study_first_submitted_qc>May 7, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 9, 2007</study_first_posted>
  <results_first_submitted>August 2, 2017</results_first_submitted>
  <results_first_submitted_qc>August 3, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">September 5, 2017</results_first_posted>
  <disposition_first_submitted>October 13, 2010</disposition_first_submitted>
  <disposition_first_submitted_qc>April 19, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">April 24, 2012</disposition_first_posted>
  <last_update_submitted>October 9, 2017</last_update_submitted>
  <last_update_submitted_qc>October 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>bone mineral density,</keyword>
  <keyword>Ronacaleret</keyword>
  <keyword>teriparatide</keyword>
  <keyword>alendronate,</keyword>
  <keyword>Post-menopausal women,</keyword>
  <keyword>osteoporosis,</keyword>
  <keyword>SB-751689</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alendronate</mesh_term>
    <mesh_term>Teriparatide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>CR9108963</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>CR9108963</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>CR9108963</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>CR9108963</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>CR9108963</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>CR9108963</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>CR9108963</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was conducted between 14-May-2007and 26-December-2008 at 45 centres in 14 countries.</recruitment_details>
      <pre_assignment_details>Of the 1609 participants screened, 1040 were screen failures, remaining 569 were randomized to the treatment arms. One participant from each of the 4 ronacaleret groups and alendronate group were excluded from Intent-to-Treat population and 564 participants were included in Intent-to-Treat population.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Participants received matching placebo once daily (OD) (matching to ronacaleret tablet) and matching placebo once weekly (OW) (matching to Alendronate capsule) for 12 months. Participants were supplied with elemental calcium 500-660 milligrams (mg) and vitamin D, at least 400 international units (IU), OD in the evening as dietary supplements throughout the study.</description>
        </group>
        <group group_id="P2">
          <title>Ronacaleret, 100 mg Tablet, OD</title>
          <description>Participants received ronacaleret, 100 mg tablet, OD and matching placebo, OW (matching to Alendronate capsule) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
        </group>
        <group group_id="P3">
          <title>Ronacaleret, 200 mg Tablet, OD</title>
          <description>Participants received ronacaleret, 200 mg tablet, OD and matching placebo, OW (matching to Alendronate capsule) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
        </group>
        <group group_id="P4">
          <title>Ronacaleret, 300 mg Tablet, OD</title>
          <description>Participants received ronacaleret, 300 mg tablet, OD and matching placebo, OW (matching to Alendronate capsule) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
        </group>
        <group group_id="P5">
          <title>Ronacaleret, 400 mg Tablet, OD</title>
          <description>Participants received Ronacaleret, 400 mg tablet, OD and matching placebo, OW (matching to Alendronate capsule) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
        </group>
        <group group_id="P6">
          <title>Alendronate, 70 mg, Capsule, OW</title>
          <description>Participants received Alendronate, 70 mg, capsule, OW and matching placebo OD (matching to ronacaleret tablet) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
        </group>
        <group group_id="P7">
          <title>Teriparatide, 20 mcg, SC Injection, OD</title>
          <description>Participants received Teriparatide, 20 microgram (mcg), subcutaneous (SC) injection, OD for 12 months. Participants were supplied with elemental calcium 500-660mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="90"/>
                <participants group_id="P2" count="87"/>
                <participants group_id="P3" count="82"/>
                <participants group_id="P4" count="88"/>
                <participants group_id="P5" count="87"/>
                <participants group_id="P6" count="89"/>
                <participants group_id="P7" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
                <participants group_id="P2" count="45"/>
                <participants group_id="P3" count="48"/>
                <participants group_id="P4" count="43"/>
                <participants group_id="P5" count="46"/>
                <participants group_id="P6" count="50"/>
                <participants group_id="P7" count="38"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="42"/>
                <participants group_id="P3" count="34"/>
                <participants group_id="P4" count="45"/>
                <participants group_id="P5" count="41"/>
                <participants group_id="P6" count="39"/>
                <participants group_id="P7" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="5"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor terminated study</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="23"/>
                <participants group_id="P3" count="19"/>
                <participants group_id="P4" count="22"/>
                <participants group_id="P5" count="18"/>
                <participants group_id="P6" count="24"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliance</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Met serum creatinine withdrawal criteria</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Early stopping due to non-efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant planned to travel to abraod</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>High parathyroid hormone</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant lost medication</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administration of prohibited medicine</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant shifted residence</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant's decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Participants received matching placebo OD (matching to ronacaleret tablet) and matching placebo OW (matching to Alendronate capsule) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
        </group>
        <group group_id="B2">
          <title>Ronacaleret, 100 mg Tablet, OD</title>
          <description>Participants received ronacaleret, 100 mg tablet, OD and matching placebo, OW (matching to Alendronate capsule) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
        </group>
        <group group_id="B3">
          <title>Ronacaleret, 200 mg Tablet, OD</title>
          <description>Participants received ronacaleret, 200 mg tablet, OD and matching placebo, OW (matching to Alendronate capsule) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
        </group>
        <group group_id="B4">
          <title>Ronacaleret, 300 mg Tablet, OD</title>
          <description>Participants received ronacaleret, 300 mg tablet, OD and matching placebo, OW (matching to Alendronate capsule) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
        </group>
        <group group_id="B5">
          <title>Ronacaleret, 400 mg Tablet, OD</title>
          <description>Participants received Ronacaleret, 400 mg tablet, OD and matching placebo, OW (matching to Alendronate capsule) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
        </group>
        <group group_id="B6">
          <title>Alendronate, 70 mg, Capsule, OW</title>
          <description>Participants received Alendronate, 70 mg, capsule, OW and matching placebo OD (matching to ronacaleret tablet) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
        </group>
        <group group_id="B7">
          <title>Teriparatide, 20 mcg, SC Injection, OD</title>
          <description>Participants received Teriparatide, 20 mcg, SC injection, OD for 12 months. Participants were supplied with elemental calcium 500-660mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
        </group>
        <group group_id="B8">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="90"/>
            <count group_id="B2" value="87"/>
            <count group_id="B3" value="82"/>
            <count group_id="B4" value="88"/>
            <count group_id="B5" value="87"/>
            <count group_id="B6" value="89"/>
            <count group_id="B7" value="41"/>
            <count group_id="B8" value="564"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.20" spread="6.75"/>
                    <measurement group_id="B2" value="64.17" spread="7.69"/>
                    <measurement group_id="B3" value="64.16" spread="7.03"/>
                    <measurement group_id="B4" value="64.34" spread="6.57"/>
                    <measurement group_id="B5" value="64.97" spread="7.60"/>
                    <measurement group_id="B6" value="65.11" spread="7.04"/>
                    <measurement group_id="B7" value="63.17" spread="5.92"/>
                    <measurement group_id="B8" value="64.24" spread="7.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="90"/>
                    <measurement group_id="B2" value="87"/>
                    <measurement group_id="B3" value="82"/>
                    <measurement group_id="B4" value="88"/>
                    <measurement group_id="B5" value="87"/>
                    <measurement group_id="B6" value="89"/>
                    <measurement group_id="B7" value="41"/>
                    <measurement group_id="B8" value="564"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participant</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>African American/African Heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="10"/>
                    <measurement group_id="B6" value="8"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73"/>
                    <measurement group_id="B2" value="71"/>
                    <measurement group_id="B3" value="66"/>
                    <measurement group_id="B4" value="73"/>
                    <measurement group_id="B5" value="71"/>
                    <measurement group_id="B6" value="76"/>
                    <measurement group_id="B7" value="35"/>
                    <measurement group_id="B8" value="465"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>African American/African Heritage &amp; White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Change From Baseline in Bone Marrow Density (BMD) at Month 12 Measured by Dual-Energy X-Ray Absorptiometry (DXA) Scans of the Lumbar Spine (L1-L4)</title>
        <description>DXA scanners from Hologic and GE Lunar was used to measure BMD by a DXA scan. At least two vertebrae (L1-L4) that were suitable for measurement of BMD were evaluated. The same scanner was used throughout the study for all measurements for a given participant. DXA scans were sent to a central reading facility for quality control and central analysis. Assessments performed on Day 0 were considered as Baseline. Percent change from Baseline was computed as (change from baseline / baseline value) * 100%. Percent change from Baseline in areal bone mineral density (aBMD) was reported.</description>
        <time_frame>Baseline (Day 0) and 12 Months</time_frame>
        <population>Intent-to-Treat population comprised of any randomised or teriparatide participant who received at least one dose of study medication. Only those participants available at the specified time points were analyzed. Teriparatide arm was excluded from the analysis, since these participants were not randomized and were disproportionately represented.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received matching placebo OD (matching to ronacaleret tablet) and matching placebo OW (matching to Alendronate capsule) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
          </group>
          <group group_id="O2">
            <title>Ronacaleret, 100 mg Tablet, OD</title>
            <description>Participants received ronacaleret, 100 mg tablet, OD and matching placebo, OW (matching to Alendronate capsule) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
          </group>
          <group group_id="O3">
            <title>Ronacaleret, 200 mg Tablet, OD</title>
            <description>Participants received ronacaleret, 200 mg tablet, OD and matching placebo, OW (matching to Alendronate capsule) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
          </group>
          <group group_id="O4">
            <title>Ronacaleret, 300 mg Tablet, OD</title>
            <description>Participants received ronacaleret, 300 mg tablet, OD and matching placebo, OW (matching to Alendronate capsule) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
          </group>
          <group group_id="O5">
            <title>Ronacaleret, 400 mg Tablet, OD</title>
            <description>Participants received Ronacaleret, 400 mg tablet, OD and matching placebo, OW (matching to Alendronate capsule) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
          </group>
          <group group_id="O6">
            <title>Alendronate, 70 mg, Capsule, OW</title>
            <description>Participants received Alendronate, 70 mg, capsule, OW and matching placebo OD (matching to ronacaleret tablet) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Bone Marrow Density (BMD) at Month 12 Measured by Dual-Energy X-Ray Absorptiometry (DXA) Scans of the Lumbar Spine (L1-L4)</title>
          <description>DXA scanners from Hologic and GE Lunar was used to measure BMD by a DXA scan. At least two vertebrae (L1-L4) that were suitable for measurement of BMD were evaluated. The same scanner was used throughout the study for all measurements for a given participant. DXA scans were sent to a central reading facility for quality control and central analysis. Assessments performed on Day 0 were considered as Baseline. Percent change from Baseline was computed as (change from baseline / baseline value) * 100%. Percent change from Baseline in areal bone mineral density (aBMD) was reported.</description>
          <population>Intent-to-Treat population comprised of any randomised or teriparatide participant who received at least one dose of study medication. Only those participants available at the specified time points were analyzed. Teriparatide arm was excluded from the analysis, since these participants were not randomized and were disproportionately represented.</population>
          <units>Percent change in BMD</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="76"/>
                <count group_id="O3" value="74"/>
                <count group_id="O4" value="78"/>
                <count group_id="O5" value="72"/>
                <count group_id="O6" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" spread="0.38"/>
                    <measurement group_id="O2" value="0.32" spread="0.40"/>
                    <measurement group_id="O3" value="1.39" spread="0.40"/>
                    <measurement group_id="O4" value="1.61" spread="0.39"/>
                    <measurement group_id="O5" value="1.62" spread="0.40"/>
                    <measurement group_id="O6" value="4.54" spread="0.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.590</p_value>
            <method>ANOVA</method>
            <method_desc>Each dose of ronacaleret was deemed significantly different from placebo if the Hommel-adjusted p-value was &lt;0.044 at Month 12.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.29</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.55</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.78</ci_lower_limit>
            <ci_upper_limit>1.37</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.028</p_value>
            <method>ANOVA</method>
            <method_desc>Each dose of ronacaleret was deemed significantly different from placebo if the Hommel-adjusted p-value was &lt;0.044 at Month 12</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>1.36</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.55</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.28</ci_lower_limit>
            <ci_upper_limit>2.44</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.011</p_value>
            <method>ANOVA</method>
            <method_desc>Each dose of ronacaleret was deemed significantly different from placebo if the Hommel-adjusted p-value was &lt;0.044 at Month 12.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>1.58</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.54</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.51</ci_lower_limit>
            <ci_upper_limit>2.65</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.012</p_value>
            <method>ANOVA</method>
            <method_desc>Each dose of ronacaleret was deemed significantly different from placebo if the Hommel-adjusted p-value was &lt;0.044 at Month 12.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>1.60</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.55</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.51</ci_lower_limit>
            <ci_upper_limit>2.69</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Hypercalcemia</title>
        <description>Participants with albumin-adjusted serum calcium pre-dose values of &gt;11.0 mg/ deciliter (dL) or post-dose values of &gt;12.0 mg/dL were recorded as participants with hypercalcemia. Number of participant with hypercalcemia were reported.</description>
        <time_frame>Up to Month 12</time_frame>
        <population>Intent-to-Treat population.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received matching placebo OD (matching to ronacaleret tablet) and matching placebo OW (matching to Alendronate capsule) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
          </group>
          <group group_id="O2">
            <title>Ronacaleret, 100 mg Tablet, OD</title>
            <description>Participants received ronacaleret, 100 mg tablet, OD and matching placebo, OW (matching to Alendronate capsule) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
          </group>
          <group group_id="O3">
            <title>Ronacaleret, 200 mg Tablet, OD</title>
            <description>Participants received ronacaleret, 200 mg tablet, OD and matching placebo, OW (matching to Alendronate capsule) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
          </group>
          <group group_id="O4">
            <title>Ronacaleret, 300 mg Tablet, OD</title>
            <description>Participants received ronacaleret, 300 mg tablet, OD and matching placebo, OW (matching to Alendronate capsule) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
          </group>
          <group group_id="O5">
            <title>Ronacaleret, 400 mg Tablet, OD</title>
            <description>Participants received Ronacaleret, 400 mg tablet, OD and matching placebo, OW (matching to Alendronate capsule) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
          </group>
          <group group_id="O6">
            <title>Alendronate, 70 mg, Capsule, OW</title>
            <description>Participants received Alendronate, 70 mg, capsule, OW and matching placebo OD (matching to ronacaleret tablet) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
          </group>
          <group group_id="O7">
            <title>Teriparatide, 20 mcg, SC Injection, OD</title>
            <description>Participants received Teriparatide, 20 mcg, SC injection, OD for 12 months. Participants were supplied with elemental calcium 500-660mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Hypercalcemia</title>
          <description>Participants with albumin-adjusted serum calcium pre-dose values of &gt;11.0 mg/ deciliter (dL) or post-dose values of &gt;12.0 mg/dL were recorded as participants with hypercalcemia. Number of participant with hypercalcemia were reported.</description>
          <population>Intent-to-Treat population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="87"/>
                <count group_id="O3" value="82"/>
                <count group_id="O4" value="88"/>
                <count group_id="O5" value="87"/>
                <count group_id="O6" value="89"/>
                <count group_id="O7" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="11"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Withdrew Due to Hypercalcemia</title>
        <description>A confirmed albumin-adjusted serum calcium pre-dose value of &gt;11.0 mg/dL or post-dose value of &gt;12.0 mg/dL was set as a withdrawal criteria for the study. Number of participants who met this pre-defined stopping criteria were reported.</description>
        <time_frame>Up to Month 12</time_frame>
        <population>Intent-to-Treat population.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received matching placebo OD (matching to ronacaleret tablet) and matching placebo OW (matching to Alendronate capsule) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
          </group>
          <group group_id="O2">
            <title>Ronacaleret, 100 mg Tablet, OD</title>
            <description>Participants received ronacaleret, 100 mg tablet, OD and matching placebo, OW (matching to Alendronate capsule) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
          </group>
          <group group_id="O3">
            <title>Ronacaleret, 200 mg Tablet, OD</title>
            <description>Participants received ronacaleret, 200 mg tablet, OD and matching placebo, OW (matching to Alendronate capsule) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
          </group>
          <group group_id="O4">
            <title>Ronacaleret, 300 mg Tablet, OD</title>
            <description>Participants received ronacaleret, 300 mg tablet, OD and matching placebo, OW (matching to Alendronate capsule) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
          </group>
          <group group_id="O5">
            <title>Ronacaleret, 400 mg Tablet, OD</title>
            <description>Participants received Ronacaleret, 400 mg tablet, OD and matching placebo, OW (matching to Alendronate capsule) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
          </group>
          <group group_id="O6">
            <title>Alendronate, 70 mg, Capsule, OW</title>
            <description>Participants received Alendronate, 70 mg, capsule, OW and matching placebo OD (matching to ronacaleret tablet) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
          </group>
          <group group_id="O7">
            <title>Teriparatide, 20 mcg, SC Injection, OD</title>
            <description>Participants received Teriparatide, 20 mcg, SC injection, OD for 12 months. Participants were supplied with elemental calcium 500-660mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Withdrew Due to Hypercalcemia</title>
          <description>A confirmed albumin-adjusted serum calcium pre-dose value of &gt;11.0 mg/dL or post-dose value of &gt;12.0 mg/dL was set as a withdrawal criteria for the study. Number of participants who met this pre-defined stopping criteria were reported.</description>
          <population>Intent-to-Treat population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="87"/>
                <count group_id="O3" value="82"/>
                <count group_id="O4" value="88"/>
                <count group_id="O5" value="87"/>
                <count group_id="O6" value="89"/>
                <count group_id="O7" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participant With Laboratory Abnormalities of Potential Clinical Concern at Any Post-baseline Visit</title>
        <description>The hematology parameters analyzed were white blood cells (WBC) count with differential WBC count, red blood cells, haemoglobin, haematocrit, mean corpuscular volume and platelet count. The clinical chemistry parameters analyzed were sodium, potassium, calcium, calcium (albumin adjusted), phosphate, bicarbonate, creatinine, bilirubin (total), alanine amino transferase, aspartate amino transferase, glucose, albumin, alkaline phosphatase, creatine phosphokinase, urea, uric acid, total protein, 25-OH vitamin D, 1,25-2(OH) vitamin D, whole parathyroid hormone (PTH 1-84)) and intact PTH (1-84 and 7-84). Only those parameters for which at least one value of potential clinical importance was reported are summarized. The number of participants with potential clinical important laboratory findings at any visit were reported.</description>
        <time_frame>Up to Month 12</time_frame>
        <population>Intent-to-Treat population.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received matching placebo OD (matching to ronacaleret tablet) and matching placebo OW (matching to Alendronate capsule) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
          </group>
          <group group_id="O2">
            <title>Ronacaleret, 100 mg Tablet, OD</title>
            <description>Participants received ronacaleret, 100 mg tablet, OD and matching placebo, OW (matching to Alendronate capsule) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
          </group>
          <group group_id="O3">
            <title>Ronacaleret, 200 mg Tablet, OD</title>
            <description>Participants received ronacaleret, 200 mg tablet, OD and matching placebo, OW (matching to Alendronate capsule) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
          </group>
          <group group_id="O4">
            <title>Ronacaleret, 300 mg Tablet, OD</title>
            <description>Participants received ronacaleret, 300 mg tablet, OD and matching placebo, OW (matching to Alendronate capsule) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
          </group>
          <group group_id="O5">
            <title>Ronacaleret, 400 mg Tablet, OD</title>
            <description>Participants received Ronacaleret, 400 mg tablet, OD and matching placebo, OW (matching to Alendronate capsule) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
          </group>
          <group group_id="O6">
            <title>Alendronate, 70 mg, Capsule, OW</title>
            <description>Participants received Alendronate, 70 mg, capsule, OW and matching placebo OD (matching to ronacaleret tablet) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
          </group>
          <group group_id="O7">
            <title>Teriparatide, 20 mcg, SC Injection, OD</title>
            <description>Participants received Teriparatide, 20 mcg, SC injection, OD for 12 months. Participants were supplied with elemental calcium 500-660mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participant With Laboratory Abnormalities of Potential Clinical Concern at Any Post-baseline Visit</title>
          <description>The hematology parameters analyzed were white blood cells (WBC) count with differential WBC count, red blood cells, haemoglobin, haematocrit, mean corpuscular volume and platelet count. The clinical chemistry parameters analyzed were sodium, potassium, calcium, calcium (albumin adjusted), phosphate, bicarbonate, creatinine, bilirubin (total), alanine amino transferase, aspartate amino transferase, glucose, albumin, alkaline phosphatase, creatine phosphokinase, urea, uric acid, total protein, 25-OH vitamin D, 1,25-2(OH) vitamin D, whole parathyroid hormone (PTH 1-84)) and intact PTH (1-84 and 7-84). Only those parameters for which at least one value of potential clinical importance was reported are summarized. The number of participants with potential clinical important laboratory findings at any visit were reported.</description>
          <population>Intent-to-Treat population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="87"/>
                <count group_id="O3" value="82"/>
                <count group_id="O4" value="88"/>
                <count group_id="O5" value="87"/>
                <count group_id="O6" value="89"/>
                <count group_id="O7" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Monocytes- high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="19"/>
                    <measurement group_id="O4" value="17"/>
                    <measurement group_id="O5" value="18"/>
                    <measurement group_id="O6" value="28"/>
                    <measurement group_id="O7" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total neutrophils- high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="10"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="6"/>
                    <measurement group_id="O7" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total neutrophils- low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="14"/>
                    <measurement group_id="O6" value="13"/>
                    <measurement group_id="O7" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils- high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="18"/>
                    <measurement group_id="O5" value="19"/>
                    <measurement group_id="O6" value="11"/>
                    <measurement group_id="O7" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose- high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="5"/>
                    <measurement group_id="O7" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose- low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Basophils- high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hematocrit- low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin- high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin- low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets- high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White Blood Cell- high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White Blood Cell- low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium- high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phosphorus- high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alkaline Phosphatase- high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total bilirubin- high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participant With Vital Signs of Potential Clinical Concern at Any Post-baseline Visit</title>
        <description>The potential clinical importance ranges (low and high) of the vital sign parameters-systolic blood pressure (&gt; 30 millimeter of mercury [mmHg] decrease from Baseline, &gt; 30 mmHg increase from Baseline), diastolic blood pressure (&gt; 20 mmHg decrease from Baseline and &gt; 20 mmHg increase from Baseline) and heart rate (&lt;45 and &gt;120 beats per minute). Only those parameters for which at least one value of potential clinical importance was reported are summarized. The number of participants with potential clinical important vital parameter findings at any visit were reported.</description>
        <time_frame>Up to 12 Months</time_frame>
        <population>Intent-to-Treat population.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received matching placebo OD (matching to ronacaleret tablet) and matching placebo OW (matching to Alendronate capsule) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
          </group>
          <group group_id="O2">
            <title>Ronacaleret, 100 mg Tablet, OD</title>
            <description>Participants received ronacaleret, 100 mg tablet, OD and matching placebo, OW (matching to Alendronate capsule) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
          </group>
          <group group_id="O3">
            <title>Ronacaleret, 200 mg Tablet, OD</title>
            <description>Participants received ronacaleret, 200 mg tablet, OD and matching placebo, OW (matching to Alendronate capsule) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
          </group>
          <group group_id="O4">
            <title>Ronacaleret, 300 mg Tablet, OD</title>
            <description>Participants received ronacaleret, 300 mg tablet, OD and matching placebo, OW (matching to Alendronate capsule) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
          </group>
          <group group_id="O5">
            <title>Ronacaleret, 400 mg Tablet, OD</title>
            <description>Participants received Ronacaleret, 400 mg tablet, OD and matching placebo, OW (matching to Alendronate capsule) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
          </group>
          <group group_id="O6">
            <title>Alendronate, 70 mg, Capsule, OW</title>
            <description>Participants received Alendronate, 70 mg, capsule, OW and matching placebo OD (matching to ronacaleret tablet) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
          </group>
          <group group_id="O7">
            <title>Teriparatide, 20 mcg, SC Injection, OD</title>
            <description>Participants received Teriparatide, 20 mcg, SC injection, OD for 12 months. Participants were supplied with elemental calcium 500-660mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participant With Vital Signs of Potential Clinical Concern at Any Post-baseline Visit</title>
          <description>The potential clinical importance ranges (low and high) of the vital sign parameters-systolic blood pressure (&gt; 30 millimeter of mercury [mmHg] decrease from Baseline, &gt; 30 mmHg increase from Baseline), diastolic blood pressure (&gt; 20 mmHg decrease from Baseline and &gt; 20 mmHg increase from Baseline) and heart rate (&lt;45 and &gt;120 beats per minute). Only those parameters for which at least one value of potential clinical importance was reported are summarized. The number of participants with potential clinical important vital parameter findings at any visit were reported.</description>
          <population>Intent-to-Treat population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="87"/>
                <count group_id="O3" value="82"/>
                <count group_id="O4" value="88"/>
                <count group_id="O5" value="87"/>
                <count group_id="O6" value="89"/>
                <count group_id="O7" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Systolic Blood Pressure, High</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="87"/>
                    <count group_id="O2" value="85"/>
                    <count group_id="O3" value="82"/>
                    <count group_id="O4" value="87"/>
                    <count group_id="O5" value="87"/>
                    <count group_id="O6" value="89"/>
                    <count group_id="O7" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="9"/>
                    <measurement group_id="O5" value="11"/>
                    <measurement group_id="O6" value="8"/>
                    <measurement group_id="O7" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systolic Blood Pressure, Low</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="87"/>
                    <count group_id="O2" value="85"/>
                    <count group_id="O3" value="82"/>
                    <count group_id="O4" value="87"/>
                    <count group_id="O5" value="87"/>
                    <count group_id="O6" value="89"/>
                    <count group_id="O7" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="8"/>
                    <measurement group_id="O7" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic Blood Pressure, High</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="87"/>
                    <count group_id="O2" value="85"/>
                    <count group_id="O3" value="82"/>
                    <count group_id="O4" value="87"/>
                    <count group_id="O5" value="87"/>
                    <count group_id="O6" value="89"/>
                    <count group_id="O7" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic Blood Pressure, Low</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="87"/>
                    <count group_id="O2" value="85"/>
                    <count group_id="O3" value="82"/>
                    <count group_id="O4" value="87"/>
                    <count group_id="O5" value="87"/>
                    <count group_id="O6" value="89"/>
                    <count group_id="O7" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="12"/>
                    <measurement group_id="O5" value="10"/>
                    <measurement group_id="O6" value="10"/>
                    <measurement group_id="O7" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Heart Rate, Low</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="87"/>
                    <count group_id="O2" value="85"/>
                    <count group_id="O3" value="82"/>
                    <count group_id="O4" value="87"/>
                    <count group_id="O5" value="87"/>
                    <count group_id="O6" value="89"/>
                    <count group_id="O7" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participant With Electrocardiogram (ECG) Findings Reported as Adverse Event</title>
        <description>Full 12-lead ECGs pre-dose at screening and visits 6, 8, 11, 12 and 14 were recorded. Participants rested supine or seated for at least 10 minutes before each reading. All ECGs were transmitted to a central reviewer for blinded assessment. The central reviewer measured the following parameters and provide a clinical interpretation: heart rate, RR interval, PR interval, QRS interval, QT (uncorrected) interval, QTcB (Bazett’s correction) interval, QTcF (Fridericia’s correction) interval. The central reviewer was provided the investigator or designated qualified site physician with a central ECG report or confirmatory report to assist them in identifying any clinically significant abnormalities that would preclude the participant from further participation in the study.</description>
        <time_frame>Up to 12 months</time_frame>
        <population>Intent-to-Treat population.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received matching placebo OD (matching to ronacaleret tablet) and matching placebo OW (matching to Alendronate capsule) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
          </group>
          <group group_id="O2">
            <title>Ronacaleret, 100 mg Tablet, OD</title>
            <description>Participants received ronacaleret, 100 mg tablet, OD and matching placebo, OW (matching to Alendronate capsule) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
          </group>
          <group group_id="O3">
            <title>Ronacaleret, 200 mg Tablet, OD</title>
            <description>Participants received ronacaleret, 200 mg tablet, OD and matching placebo, OW (matching to Alendronate capsule) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
          </group>
          <group group_id="O4">
            <title>Ronacaleret, 300 mg Tablet, OD</title>
            <description>Participants received ronacaleret, 300 mg tablet, OD and matching placebo, OW (matching to Alendronate capsule) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
          </group>
          <group group_id="O5">
            <title>Ronacaleret, 400 mg Tablet, OD</title>
            <description>Participants received Ronacaleret, 400 mg tablet, OD and matching placebo, OW (matching to Alendronate capsule) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
          </group>
          <group group_id="O6">
            <title>Alendronate, 70 mg, Capsule, OW</title>
            <description>Participants received Alendronate, 70 mg, capsule, OW and matching placebo OD (matching to ronacaleret tablet) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
          </group>
          <group group_id="O7">
            <title>Teriparatide, 20 mcg, SC Injection, OD</title>
            <description>Participants received Teriparatide, 20 mcg, SC injection, OD for 12 months. Participants were supplied with elemental calcium 500-660mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participant With Electrocardiogram (ECG) Findings Reported as Adverse Event</title>
          <description>Full 12-lead ECGs pre-dose at screening and visits 6, 8, 11, 12 and 14 were recorded. Participants rested supine or seated for at least 10 minutes before each reading. All ECGs were transmitted to a central reviewer for blinded assessment. The central reviewer measured the following parameters and provide a clinical interpretation: heart rate, RR interval, PR interval, QRS interval, QT (uncorrected) interval, QTcB (Bazett’s correction) interval, QTcF (Fridericia’s correction) interval. The central reviewer was provided the investigator or designated qualified site physician with a central ECG report or confirmatory report to assist them in identifying any clinically significant abnormalities that would preclude the participant from further participation in the study.</description>
          <population>Intent-to-Treat population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="87"/>
                <count group_id="O3" value="82"/>
                <count group_id="O4" value="88"/>
                <count group_id="O5" value="87"/>
                <count group_id="O6" value="89"/>
                <count group_id="O7" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="5"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Change From Baseline in Height</title>
        <description>Assessments performed on Day 0 were considered as Baseline. Change from Baseline was computed as values at post baseline visit minus Baseline value. Mean change from baseline in height at Month 6 and 12 and early withdrawal were reported.</description>
        <time_frame>Baseline (Day 0), Month 6, 12 and early withdrawal</time_frame>
        <population>Intent-to-Treat population. Only those participants available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received matching placebo OD (matching to ronacaleret tablet) and matching placebo OW (matching to Alendronate capsule) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
          </group>
          <group group_id="O2">
            <title>Ronacaleret, 100 mg Tablet, OD</title>
            <description>Participants received ronacaleret, 100 mg tablet, OD and matching placebo, OW (matching to Alendronate capsule) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
          </group>
          <group group_id="O3">
            <title>Ronacaleret, 200 mg Tablet, OD</title>
            <description>Participants received ronacaleret, 200 mg tablet, OD and matching placebo, OW (matching to Alendronate capsule) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
          </group>
          <group group_id="O4">
            <title>Ronacaleret, 300 mg Tablet, OD</title>
            <description>Participants received ronacaleret, 300 mg tablet, OD and matching placebo, OW (matching to Alendronate capsule) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
          </group>
          <group group_id="O5">
            <title>Ronacaleret, 400 mg Tablet, OD</title>
            <description>Participants received Ronacaleret, 400 mg tablet, OD and matching placebo, OW (matching to Alendronate capsule) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
          </group>
          <group group_id="O6">
            <title>Alendronate, 70 mg, Capsule, OW</title>
            <description>Participants received Alendronate, 70 mg, capsule, OW and matching placebo OD (matching to ronacaleret tablet) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
          </group>
          <group group_id="O7">
            <title>Teriparatide, 20 mcg, SC Injection, OD</title>
            <description>Participants received Teriparatide, 20 mcg, SC injection, OD for 12 months. Participants were supplied with elemental calcium 500-660mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Height</title>
          <description>Assessments performed on Day 0 were considered as Baseline. Change from Baseline was computed as values at post baseline visit minus Baseline value. Mean change from baseline in height at Month 6 and 12 and early withdrawal were reported.</description>
          <population>Intent-to-Treat population. Only those participants available at the specified time points were analyzed.</population>
          <units>Centimeter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="87"/>
                <count group_id="O3" value="82"/>
                <count group_id="O4" value="88"/>
                <count group_id="O5" value="87"/>
                <count group_id="O6" value="89"/>
                <count group_id="O7" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="68"/>
                    <count group_id="O2" value="70"/>
                    <count group_id="O3" value="68"/>
                    <count group_id="O4" value="75"/>
                    <count group_id="O5" value="70"/>
                    <count group_id="O6" value="74"/>
                    <count group_id="O7" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.04" spread="0.58"/>
                    <measurement group_id="O2" value="0.17" spread="1.41"/>
                    <measurement group_id="O3" value="0.72" spread="3.82"/>
                    <measurement group_id="O4" value="0.05" spread="0.70"/>
                    <measurement group_id="O5" value="-0.04" spread="0.82"/>
                    <measurement group_id="O6" value="-0.07" spread="1.13"/>
                    <measurement group_id="O7" value="0.11" spread="0.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="49"/>
                    <count group_id="O2" value="45"/>
                    <count group_id="O3" value="48"/>
                    <count group_id="O4" value="43"/>
                    <count group_id="O5" value="41"/>
                    <count group_id="O6" value="50"/>
                    <count group_id="O7" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.14" spread="0.65"/>
                    <measurement group_id="O2" value="0.04" spread="1.59"/>
                    <measurement group_id="O3" value="0.02" spread="0.76"/>
                    <measurement group_id="O4" value="-0.09" spread="1.04"/>
                    <measurement group_id="O5" value="-0.17" spread="0.67"/>
                    <measurement group_id="O6" value="-0.08" spread="0.57"/>
                    <measurement group_id="O7" value="0.11" spread="0.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Early withdrawal</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="36"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="37"/>
                    <count group_id="O5" value="31"/>
                    <count group_id="O6" value="35"/>
                    <count group_id="O7" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" spread="0.61"/>
                    <measurement group_id="O2" value="0.17" spread="1.92"/>
                    <measurement group_id="O3" value="-0.13" spread="0.55"/>
                    <measurement group_id="O4" value="-0.16" spread="0.76"/>
                    <measurement group_id="O5" value="-0.16" spread="0.82"/>
                    <measurement group_id="O6" value="-0.37" spread="0.88"/>
                    <measurement group_id="O7" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Change From Baseline in Weight</title>
        <description>Baseline values were assessed on Day 0. Change from Baseline was computed as values at post baseline visit minus Baseline value. Mean change from baseline in weight at Month 6, 12 and early withdrawal were reported.</description>
        <time_frame>Baseline (Day 0), Month 6, 12 and early withdrawal</time_frame>
        <population>Intent-to-Treat population. Only those participants available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received matching placebo OD (matching to ronacaleret tablet) and matching placebo OW (matching to Alendronate capsule) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
          </group>
          <group group_id="O2">
            <title>Ronacaleret, 100 mg Tablet, OD</title>
            <description>Participants received ronacaleret, 100 mg tablet, OD and matching placebo, OW (matching to Alendronate capsule) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
          </group>
          <group group_id="O3">
            <title>Ronacaleret, 200 mg Tablet, OD</title>
            <description>Participants received ronacaleret, 200 mg tablet, OD and matching placebo, OW (matching to Alendronate capsule) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
          </group>
          <group group_id="O4">
            <title>Ronacaleret, 300 mg Tablet, OD</title>
            <description>Participants received ronacaleret, 300 mg tablet, OD and matching placebo, OW (matching to Alendronate capsule) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
          </group>
          <group group_id="O5">
            <title>Ronacaleret, 400 mg Tablet, OD</title>
            <description>Participants received Ronacaleret, 400 mg tablet, OD and matching placebo, OW (matching to Alendronate capsule) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
          </group>
          <group group_id="O6">
            <title>Alendronate, 70 mg, Capsule, OW</title>
            <description>Participants received Alendronate, 70 mg, capsule, OW and matching placebo OD (matching to ronacaleret tablet) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
          </group>
          <group group_id="O7">
            <title>Teriparatide, 20 mcg, SC Injection, OD</title>
            <description>Participants received Teriparatide, 20 mcg, SC injection, OD for 12 months. Participants were supplied with elemental calcium 500-660mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Weight</title>
          <description>Baseline values were assessed on Day 0. Change from Baseline was computed as values at post baseline visit minus Baseline value. Mean change from baseline in weight at Month 6, 12 and early withdrawal were reported.</description>
          <population>Intent-to-Treat population. Only those participants available at the specified time points were analyzed.</population>
          <units>Kilogram</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="87"/>
                <count group_id="O3" value="82"/>
                <count group_id="O4" value="88"/>
                <count group_id="O5" value="87"/>
                <count group_id="O6" value="89"/>
                <count group_id="O7" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="70"/>
                    <count group_id="O3" value="68"/>
                    <count group_id="O4" value="75"/>
                    <count group_id="O5" value="70"/>
                    <count group_id="O6" value="74"/>
                    <count group_id="O7" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.02" spread="2.12"/>
                    <measurement group_id="O2" value="0.27" spread="3.27"/>
                    <measurement group_id="O3" value="0.45" spread="2.98"/>
                    <measurement group_id="O4" value="-0.24" spread="2.87"/>
                    <measurement group_id="O5" value="0.11" spread="2.84"/>
                    <measurement group_id="O6" value="0.29" spread="1.89"/>
                    <measurement group_id="O7" value="0.51" spread="1.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="49"/>
                    <count group_id="O2" value="45"/>
                    <count group_id="O3" value="48"/>
                    <count group_id="O4" value="43"/>
                    <count group_id="O5" value="47"/>
                    <count group_id="O6" value="50"/>
                    <count group_id="O7" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.32" spread="2.73"/>
                    <measurement group_id="O2" value="-0.72" spread="2.70"/>
                    <measurement group_id="O3" value="1.18" spread="9.78"/>
                    <measurement group_id="O4" value="-0.22" spread="2.36"/>
                    <measurement group_id="O5" value="-0.48" spread="2.28"/>
                    <measurement group_id="O6" value="0.57" spread="3.22"/>
                    <measurement group_id="O7" value="0.09" spread="2.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Early withdrawal</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="36"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="37"/>
                    <count group_id="O5" value="32"/>
                    <count group_id="O6" value="35"/>
                    <count group_id="O7" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.45" spread="2.40"/>
                    <measurement group_id="O2" value="0.40" spread="4.60"/>
                    <measurement group_id="O3" value="-0.34" spread="2.48"/>
                    <measurement group_id="O4" value="0.37" spread="3.86"/>
                    <measurement group_id="O5" value="0.00" spread="2.17"/>
                    <measurement group_id="O6" value="-0.12" spread="2.33"/>
                    <measurement group_id="O7" value="-2.15" spread="1.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Month 6 in BMD Measured by DXA Scans of the Lumbar Spine (L1-L4)</title>
        <description>DXA scanners from Hologic and GE Lunar was used to measure BMD by a DXA scan. At least two vertebrae (L1-L4) that were suitable for measurement of BMD were evaluated. The same scanner was used throughout the study for all measurements for a given participant. DXA scans were sent to a central reading facility for quality control and central analysis. Baseline values were assessed on Day 0. Percent Change from Baseline was computed as (change from baseline / baseline value) * 100%. Percent change from baseline to month 6 in aBMD was reported.</description>
        <time_frame>Baseline (Day 0) and Month 6</time_frame>
        <population>Intent to Treat Population. Only those participants available at the specified time point were analyzed. Participants from Teriparatide, 20 mcg, SC injection, OD arm were excluded from the analysis, since these participants were not randomized and were disproportionately represented.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received matching placebo OD (matching to ronacaleret tablet) and matching placebo OW (matching to Alendronate capsule) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
          </group>
          <group group_id="O2">
            <title>Ronacaleret, 100 mg Tablet, OD</title>
            <description>Participants received ronacaleret, 100 mg tablet, OD and matching placebo, OW (matching to Alendronate capsule) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
          </group>
          <group group_id="O3">
            <title>Ronacaleret, 200 mg Tablet, OD</title>
            <description>Participants received ronacaleret, 200 mg tablet, OD and matching placebo, OW (matching to Alendronate capsule) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
          </group>
          <group group_id="O4">
            <title>Ronacaleret, 300 mg Tablet, OD</title>
            <description>Participants received ronacaleret, 300 mg tablet, OD and matching placebo, OW (matching to Alendronate capsule) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
          </group>
          <group group_id="O5">
            <title>Ronacaleret, 400 mg Tablet, OD</title>
            <description>Participants received Ronacaleret, 400 mg tablet, OD and matching placebo, OW (matching to Alendronate capsule) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
          </group>
          <group group_id="O6">
            <title>Alendronate, 70 mg, Capsule, OW</title>
            <description>Participants received Alendronate, 70 mg, capsule, OW and matching placebo OD (matching to ronacaleret tablet) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Month 6 in BMD Measured by DXA Scans of the Lumbar Spine (L1-L4)</title>
          <description>DXA scanners from Hologic and GE Lunar was used to measure BMD by a DXA scan. At least two vertebrae (L1-L4) that were suitable for measurement of BMD were evaluated. The same scanner was used throughout the study for all measurements for a given participant. DXA scans were sent to a central reading facility for quality control and central analysis. Baseline values were assessed on Day 0. Percent Change from Baseline was computed as (change from baseline / baseline value) * 100%. Percent change from baseline to month 6 in aBMD was reported.</description>
          <population>Intent to Treat Population. Only those participants available at the specified time point were analyzed. Participants from Teriparatide, 20 mcg, SC injection, OD arm were excluded from the analysis, since these participants were not randomized and were disproportionately represented.</population>
          <units>percent change in BMD</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="76"/>
                <count group_id="O3" value="74"/>
                <count group_id="O4" value="77"/>
                <count group_id="O5" value="73"/>
                <count group_id="O6" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.66" spread="0.33"/>
                    <measurement group_id="O2" value="0.21" spread="0.34"/>
                    <measurement group_id="O3" value="1.61" spread="0.35"/>
                    <measurement group_id="O4" value="0.47" spread="0.34"/>
                    <measurement group_id="O5" value="1.01" spread="0.35"/>
                    <measurement group_id="O6" value="3.42" spread="0.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.680</p_value>
            <method>ANOVA</method>
            <method_desc>Each dose of ronacaleret was deemed significantly different from placebo if the Hommel-adjusted p-value was &lt;0.006 at Month 6.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.45</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.47</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.38</ci_lower_limit>
            <ci_upper_limit>0.48</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.192</p_value>
            <method>ANOVA</method>
            <method_desc>Each dose of ronacaleret was deemed significantly different from placebo if the Hommel-adjusted p-value was &lt;0.006 at Month 6.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.95</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.48</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.01</ci_lower_limit>
            <ci_upper_limit>1.89</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.680</p_value>
            <method>ANOVA</method>
            <method_desc>Each dose of ronacaleret was deemed significantly different from placebo if the Hommel-adjusted p-value was &lt;0.006 at Month 6.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.19</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.47</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.12</ci_lower_limit>
            <ci_upper_limit>0.73</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.680</p_value>
            <method>ANOVA</method>
            <method_desc>Each dose of ronacaleret was deemed significantly different from placebo if the Hommel-adjusted p-value was &lt;0.006 at Month 6.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.35</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.48</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.59</ci_lower_limit>
            <ci_upper_limit>1.29</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Months 6 and 12 in BMD Measured by DXA Scans of the Hip (Total Hip, Femoral Neck and Trochanter).</title>
        <description>DXA scanners from Hologic and GE Lunar was used to measure BMD by a DXA scan. At least two vertebrae (L1-L4) that were suitable for measurement of BMD were evaluated. The same scanner was used throughout the study for all measurements for a given participant. DXA scans were sent to a central reading facility for quality control and central analysis. Baseline values were assessed on Day 0. Percent Change from Baseline was computed as (change from baseline / baseline value) * 100%. Percent change from baseline to month 6 and 12 in aBMD of hip (total hip, femoral neck and trochanter) were reported.</description>
        <time_frame>Baseline (Day 0), Month 6 and Month 12</time_frame>
        <population>Intent-to-Treat population. Only those participants available at the specified time points were analyzed. Participants from Teriparatide, 20 mcg, SC injection, OD arm were excluded from the analysis, since these participants were not randomized and were disproportionately represented.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received matching placebo OD (matching to ronacaleret tablet) and matching placebo OW (matching to Alendronate capsule) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
          </group>
          <group group_id="O2">
            <title>Ronacaleret, 100 mg Tablet, OD</title>
            <description>Participants received ronacaleret, 100 mg tablet, OD and matching placebo, OW (matching to Alendronate capsule) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
          </group>
          <group group_id="O3">
            <title>Ronacaleret, 200 mg Tablet, OD</title>
            <description>Participants received ronacaleret, 200 mg tablet, OD and matching placebo, OW (matching to Alendronate capsule) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
          </group>
          <group group_id="O4">
            <title>Ronacaleret, 300 mg Tablet, OD</title>
            <description>Participants received ronacaleret, 300 mg tablet, OD and matching placebo, OW (matching to Alendronate capsule) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
          </group>
          <group group_id="O5">
            <title>Ronacaleret, 400 mg Tablet, OD</title>
            <description>Participants received Ronacaleret, 400 mg tablet, OD and matching placebo, OW (matching to Alendronate capsule) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
          </group>
          <group group_id="O6">
            <title>Alendronate, 70 mg, Capsule, OW</title>
            <description>Participants received Alendronate, 70 mg, capsule, OW and matching placebo OD (matching to ronacaleret tablet) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Months 6 and 12 in BMD Measured by DXA Scans of the Hip (Total Hip, Femoral Neck and Trochanter).</title>
          <description>DXA scanners from Hologic and GE Lunar was used to measure BMD by a DXA scan. At least two vertebrae (L1-L4) that were suitable for measurement of BMD were evaluated. The same scanner was used throughout the study for all measurements for a given participant. DXA scans were sent to a central reading facility for quality control and central analysis. Baseline values were assessed on Day 0. Percent Change from Baseline was computed as (change from baseline / baseline value) * 100%. Percent change from baseline to month 6 and 12 in aBMD of hip (total hip, femoral neck and trochanter) were reported.</description>
          <population>Intent-to-Treat population. Only those participants available at the specified time points were analyzed. Participants from Teriparatide, 20 mcg, SC injection, OD arm were excluded from the analysis, since these participants were not randomized and were disproportionately represented.</population>
          <units>Percent change in BMD</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="87"/>
                <count group_id="O3" value="82"/>
                <count group_id="O4" value="88"/>
                <count group_id="O5" value="87"/>
                <count group_id="O6" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total Hip aBMD, Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="79"/>
                    <count group_id="O2" value="75"/>
                    <count group_id="O3" value="74"/>
                    <count group_id="O4" value="77"/>
                    <count group_id="O5" value="71"/>
                    <count group_id="O6" value="74"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.42" spread="0.23"/>
                    <measurement group_id="O2" value="-0.26" spread="0.24"/>
                    <measurement group_id="O3" value="-0.37" spread="0.24"/>
                    <measurement group_id="O4" value="-0.86" spread="0.23"/>
                    <measurement group_id="O5" value="-0.88" spread="0.24"/>
                    <measurement group_id="O6" value="1.84" spread="0.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Hip aBMD, Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="79"/>
                    <count group_id="O2" value="75"/>
                    <count group_id="O3" value="74"/>
                    <count group_id="O4" value="78"/>
                    <count group_id="O5" value="70"/>
                    <count group_id="O6" value="74"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.27" spread="0.26"/>
                    <measurement group_id="O2" value="-0.62" spread="0.26"/>
                    <measurement group_id="O3" value="-0.75" spread="0.27"/>
                    <measurement group_id="O4" value="-1.07" spread="0.26"/>
                    <measurement group_id="O5" value="-1.31" spread="0.27"/>
                    <measurement group_id="O6" value="2.70" spread="0.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Total Hip aBMD, Month 6</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.037</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.68</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.33</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.32</ci_lower_limit>
            <ci_upper_limit>-0.04</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Total Hip aBMD, Month 6</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.017</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.79</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.33</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.43</ci_lower_limit>
            <ci_upper_limit>-0.14</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Total Hip aBMD, Month 6</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.000</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-1.28</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.32</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.92</ci_lower_limit>
            <ci_upper_limit>-0.64</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Total Hip aBMD, Month 6</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.000</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-1.30</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.33</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.95</ci_lower_limit>
            <ci_upper_limit>-0.65</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Total Hip aBMD, Month 12</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.015</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.89</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.36</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.61</ci_lower_limit>
            <ci_upper_limit>-0.17</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Total Hip aBMD, Month 12</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.006</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-1.02</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.37</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.74</ci_lower_limit>
            <ci_upper_limit>-0.30</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Total Hip aBMD, Month 12</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.000</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-1.33</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.36</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.04</ci_lower_limit>
            <ci_upper_limit>-0.63</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Total Hip aBMD, Month 12</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.000</p_value>
            <method>ANOVA</method>
            <param_type>Median Difference (Net)</param_type>
            <param_value>-1.57</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.37</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.30</ci_lower_limit>
            <ci_upper_limit>-0.84</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Remained the Same or Had Any Improvement in DXA BMD (&gt; Baseline)</title>
        <description>Responder rate of participants who remained the same or had any improvement as compared to baseline in DXA BMD of vertebra, femur and vertebra plus femur were reported. Baseline values were assessed on Day 0. Percent change (improvement) from Baseline was computed as (change from baseline / baseline value) * 100%.</description>
        <time_frame>Baseline (Day 0), Month 5, 6 and 12</time_frame>
        <population>Intent-to-Treat population. Only those participants available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received matching placebo OD (matching to ronacaleret tablet) and matching placebo OW (matching to Alendronate capsule) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
          </group>
          <group group_id="O2">
            <title>Ronacaleret, 100 mg Tablet, OD</title>
            <description>Participants received ronacaleret, 100 mg tablet, OD and matching placebo, OW (matching to Alendronate capsule) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
          </group>
          <group group_id="O3">
            <title>Ronacaleret, 200 mg Tablet, OD</title>
            <description>Participants received ronacaleret, 200 mg tablet, OD and matching placebo, OW (matching to Alendronate capsule) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
          </group>
          <group group_id="O4">
            <title>Ronacaleret, 300 mg Tablet, OD</title>
            <description>Participants received ronacaleret, 300 mg tablet, OD and matching placebo, OW (matching to Alendronate capsule) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
          </group>
          <group group_id="O5">
            <title>Ronacaleret, 400 mg Tablet, OD</title>
            <description>Participants received Ronacaleret, 400 mg tablet, OD and matching placebo, OW (matching to Alendronate capsule) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
          </group>
          <group group_id="O6">
            <title>Alendronate, 70 mg, Capsule, OW</title>
            <description>Participants received Alendronate, 70 mg, capsule, OW and matching placebo OD (matching to ronacaleret tablet) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
          </group>
          <group group_id="O7">
            <title>Teriparatide, 20 mcg, SC Injection, OD</title>
            <description>Participants received Teriparatide, 20 mcg, SC injection, OD for 12 months. Participants were supplied with elemental calcium 500-660mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Remained the Same or Had Any Improvement in DXA BMD (&gt; Baseline)</title>
          <description>Responder rate of participants who remained the same or had any improvement as compared to baseline in DXA BMD of vertebra, femur and vertebra plus femur were reported. Baseline values were assessed on Day 0. Percent change (improvement) from Baseline was computed as (change from baseline / baseline value) * 100%.</description>
          <population>Intent-to-Treat population. Only those participants available at the specified time points were analyzed.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="87"/>
                <count group_id="O3" value="82"/>
                <count group_id="O4" value="88"/>
                <count group_id="O5" value="87"/>
                <count group_id="O6" value="89"/>
                <count group_id="O7" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 5, Vertebra, BMD % change &gt;=0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 5, Femur, BMD % change &gt;=0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 5, Vertebra + Femur, BMD % change &gt;=0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6, Vertebra, BMD % change &gt;=0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="1"/>
                    <count group_id="O7" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6, Femur, BMD % change &gt;=0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="1"/>
                    <count group_id="O7" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6, Vertebra + Femur, BMD % change &gt;=0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="1"/>
                    <count group_id="O7" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12, Vertebra, BMD % change &gt;=0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="50"/>
                    <count group_id="O3" value="43"/>
                    <count group_id="O4" value="43"/>
                    <count group_id="O5" value="41"/>
                    <count group_id="O6" value="49"/>
                    <count group_id="O7" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="29"/>
                    <measurement group_id="O3" value="32"/>
                    <measurement group_id="O4" value="35"/>
                    <measurement group_id="O5" value="31"/>
                    <measurement group_id="O6" value="44"/>
                    <measurement group_id="O7" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12, Femur, BMD % change &gt;=0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="47"/>
                    <count group_id="O3" value="40"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="37"/>
                    <count group_id="O6" value="45"/>
                    <count group_id="O7" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="19"/>
                    <measurement group_id="O5" value="16"/>
                    <measurement group_id="O6" value="40"/>
                    <measurement group_id="O7" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12, Vertebra + Femur, BMD % change &gt;=0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="47"/>
                    <count group_id="O3" value="40"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="37"/>
                    <count group_id="O6" value="42"/>
                    <count group_id="O7" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="17"/>
                    <measurement group_id="O5" value="16"/>
                    <measurement group_id="O6" value="35"/>
                    <measurement group_id="O7" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Early Withdrawal, Vertebra, BMD % change &gt;=0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Early Withdrawal, Femur, BMD % change &gt;=0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Early Withdrawal, Vertebra + Femur, BMD %change&gt;=0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Month 12 in the Volumetric Integral, Cortical, and Trabecular Density (BMD) at the Hip and Lumbar Spine as Measured by Quantitative Computer Tomography (QCT) Scans</title>
        <description>QCT is a three-dimensional non-projectional technique to quantify BMD with a number of advantages to other densitometric techniques. Cortical and trabecular bone can be separated, trabecular volume of interest (VOI) are largely independent of degenerative changes in the spine and 3 dimensional geometric parameters can be determined. BMD as measured by QCT is a true density measured in g/cm^3 in contrast to DXA Which determines an areal density measured in g/cm^2. Baseline values were assessed on Day 0. Percent change from Baseline was computed as (change from baseline / baseline value) * 100%. Percent change from Baseline to month 12 in the volumetric integral, cortical, and trabecular density (BMD) at the hip and lumbar spine measured by QCT were reported.</description>
        <time_frame>Baseline (Day 0) and Month 12</time_frame>
        <population>Intent-to-Treat population. Only those participants available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received matching placebo OD (matching to ronacaleret tablet) and matching placebo OW (matching to Alendronate capsule) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
          </group>
          <group group_id="O2">
            <title>Ronacaleret, 100 mg Tablet, OD</title>
            <description>Participants received ronacaleret, 100 mg tablet, OD and matching placebo, OW (matching to Alendronate capsule) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
          </group>
          <group group_id="O3">
            <title>Ronacaleret, 200 mg Tablet, OD</title>
            <description>Participants received ronacaleret, 200 mg tablet, OD and matching placebo, OW (matching to Alendronate capsule) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
          </group>
          <group group_id="O4">
            <title>Ronacaleret, 300 mg Tablet, OD</title>
            <description>Participants received ronacaleret, 300 mg tablet, OD and matching placebo, OW (matching to Alendronate capsule) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
          </group>
          <group group_id="O5">
            <title>Ronacaleret, 400 mg Tablet, OD</title>
            <description>Participants received Ronacaleret, 400 mg tablet, OD and matching placebo, OW (matching to Alendronate capsule) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
          </group>
          <group group_id="O6">
            <title>Alendronate, 70 mg, Capsule, OW</title>
            <description>Participants received Alendronate, 70 mg, capsule, OW and matching placebo OD (matching to ronacaleret tablet) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
          </group>
          <group group_id="O7">
            <title>Teriparatide, 20 mcg, SC Injection, OD</title>
            <description>Participants received Teriparatide, 20 mcg, SC injection, OD for 12 months. Participants were supplied with elemental calcium 500-660mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Month 12 in the Volumetric Integral, Cortical, and Trabecular Density (BMD) at the Hip and Lumbar Spine as Measured by Quantitative Computer Tomography (QCT) Scans</title>
          <description>QCT is a three-dimensional non-projectional technique to quantify BMD with a number of advantages to other densitometric techniques. Cortical and trabecular bone can be separated, trabecular volume of interest (VOI) are largely independent of degenerative changes in the spine and 3 dimensional geometric parameters can be determined. BMD as measured by QCT is a true density measured in g/cm^3 in contrast to DXA Which determines an areal density measured in g/cm^2. Baseline values were assessed on Day 0. Percent change from Baseline was computed as (change from baseline / baseline value) * 100%. Percent change from Baseline to month 12 in the volumetric integral, cortical, and trabecular density (BMD) at the hip and lumbar spine measured by QCT were reported.</description>
          <population>Intent-to-Treat population. Only those participants available at the specified time points were analyzed.</population>
          <units>Percent change in BMD</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="87"/>
                <count group_id="O3" value="82"/>
                <count group_id="O4" value="88"/>
                <count group_id="O5" value="87"/>
                <count group_id="O6" value="89"/>
                <count group_id="O7" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total vertebra integral VOI BMD</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="50"/>
                    <count group_id="O3" value="43"/>
                    <count group_id="O4" value="43"/>
                    <count group_id="O5" value="41"/>
                    <count group_id="O6" value="49"/>
                    <count group_id="O7" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.98" spread="3.13"/>
                    <measurement group_id="O2" value="1.09" spread="4.01"/>
                    <measurement group_id="O3" value="3.00" spread="4.98"/>
                    <measurement group_id="O4" value="3.91" spread="4.98"/>
                    <measurement group_id="O5" value="4.83" spread="6.56"/>
                    <measurement group_id="O6" value="5.04" spread="4.39"/>
                    <measurement group_id="O7" value="14.80" spread="8.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mid vertebra integral VOI BMD</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="50"/>
                    <count group_id="O3" value="43"/>
                    <count group_id="O4" value="43"/>
                    <count group_id="O5" value="41"/>
                    <count group_id="O6" value="49"/>
                    <count group_id="O7" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.31" spread="3.54"/>
                    <measurement group_id="O2" value="1.20" spread="4.85"/>
                    <measurement group_id="O3" value="4.65" spread="5.87"/>
                    <measurement group_id="O4" value="6.06" spread="6.48"/>
                    <measurement group_id="O5" value="7.33" spread="8.67"/>
                    <measurement group_id="O6" value="4.85" spread="5.25"/>
                    <measurement group_id="O7" value="17.97" spread="11.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mid Cylinder trabecular VOI BMD</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="50"/>
                    <count group_id="O3" value="43"/>
                    <count group_id="O4" value="43"/>
                    <count group_id="O5" value="41"/>
                    <count group_id="O6" value="49"/>
                    <count group_id="O7" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.45" spread="4.39"/>
                    <measurement group_id="O2" value="1.75" spread="8.70"/>
                    <measurement group_id="O3" value="6.17" spread="10.37"/>
                    <measurement group_id="O4" value="8.99" spread="10.52"/>
                    <measurement group_id="O5" value="13.29" spread="15.32"/>
                    <measurement group_id="O6" value="4.88" spread="7.68"/>
                    <measurement group_id="O7" value="24.37" spread="15.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mid Osteo trabecular VOI BMD</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="50"/>
                    <count group_id="O3" value="43"/>
                    <count group_id="O4" value="43"/>
                    <count group_id="O5" value="41"/>
                    <count group_id="O6" value="49"/>
                    <count group_id="O7" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.21" spread="4.58"/>
                    <measurement group_id="O2" value="1.81" spread="8.26"/>
                    <measurement group_id="O3" value="7.06" spread="9.25"/>
                    <measurement group_id="O4" value="9.54" spread="9.79"/>
                    <measurement group_id="O5" value="13.21" spread="14.68"/>
                    <measurement group_id="O6" value="5.15" spread="6.86"/>
                    <measurement group_id="O7" value="24.21" spread="15.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total vertebra trabecular VOI BMD</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="50"/>
                    <count group_id="O3" value="43"/>
                    <count group_id="O4" value="43"/>
                    <count group_id="O5" value="41"/>
                    <count group_id="O6" value="49"/>
                    <count group_id="O7" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.46" spread="4.58"/>
                    <measurement group_id="O2" value="1.67" spread="7.18"/>
                    <measurement group_id="O3" value="5.81" spread="8.31"/>
                    <measurement group_id="O4" value="8.52" spread="8.97"/>
                    <measurement group_id="O5" value="11.40" spread="12.83"/>
                    <measurement group_id="O6" value="4.97" spread="6.43"/>
                    <measurement group_id="O7" value="23.82" spread="14.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mid Osteo cortical VOI BMD</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="50"/>
                    <count group_id="O3" value="43"/>
                    <count group_id="O4" value="43"/>
                    <count group_id="O5" value="41"/>
                    <count group_id="O6" value="49"/>
                    <count group_id="O7" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.30" spread="4.69"/>
                    <measurement group_id="O2" value="0.63" spread="4.80"/>
                    <measurement group_id="O3" value="2.37" spread="6.37"/>
                    <measurement group_id="O4" value="2.57" spread="5.14"/>
                    <measurement group_id="O5" value="1.22" spread="4.39"/>
                    <measurement group_id="O6" value="4.98" spread="4.63"/>
                    <measurement group_id="O7" value="9.25" spread="7.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Month 12 in the Total Vertebra Integral VOI at the Lumbar Spine as Measured by QCT Scans</title>
        <description>QCT is a three-dimensional non-projectional technique to quantify BMD with a number of advantages to other densitometric techniques. Cortical and trabecular bone can be separated, trabecular VOI are largely independent of degenerative changes in the spine and 3 dimensional geometric parameters can be determined. BMD as measured by QCT is a true density measured in g/cm^3 in contrast to DXA Which determines an areal density measured in g/cm^2. Baseline values were assessed on Day 0. Percent change from Baseline was computed as (change from baseline / baseline value) * 100%.</description>
        <time_frame>Baseline (Day 0) and Month 12</time_frame>
        <population>Intent-to-Treat population. Only those participants available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received matching placebo OD (matching to ronacaleret tablet) and matching placebo OW (matching to Alendronate capsule) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
          </group>
          <group group_id="O2">
            <title>Ronacaleret, 100 mg Tablet, OD</title>
            <description>Participants received ronacaleret, 100 mg tablet, OD and matching placebo, OW (matching to Alendronate capsule) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
          </group>
          <group group_id="O3">
            <title>Ronacaleret, 200 mg Tablet, OD</title>
            <description>Participants received ronacaleret, 200 mg tablet, OD and matching placebo, OW (matching to Alendronate capsule) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
          </group>
          <group group_id="O4">
            <title>Ronacaleret, 300 mg Tablet, OD</title>
            <description>Participants received ronacaleret, 300 mg tablet, OD and matching placebo, OW (matching to Alendronate capsule) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
          </group>
          <group group_id="O5">
            <title>Ronacaleret, 400 mg Tablet, OD</title>
            <description>Participants received Ronacaleret, 400 mg tablet, OD and matching placebo, OW (matching to Alendronate capsule) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
          </group>
          <group group_id="O6">
            <title>Alendronate, 70 mg, Capsule, OW</title>
            <description>Participants received Alendronate, 70 mg, capsule, OW and matching placebo OD (matching to ronacaleret tablet) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
          </group>
          <group group_id="O7">
            <title>Teriparatide, 20 mcg, SC Injection, OD</title>
            <description>Participants received Teriparatide, 20 mcg, SC injection, OD for 12 months. Participants were supplied with elemental calcium 500-660mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Month 12 in the Total Vertebra Integral VOI at the Lumbar Spine as Measured by QCT Scans</title>
          <description>QCT is a three-dimensional non-projectional technique to quantify BMD with a number of advantages to other densitometric techniques. Cortical and trabecular bone can be separated, trabecular VOI are largely independent of degenerative changes in the spine and 3 dimensional geometric parameters can be determined. BMD as measured by QCT is a true density measured in g/cm^3 in contrast to DXA Which determines an areal density measured in g/cm^2. Baseline values were assessed on Day 0. Percent change from Baseline was computed as (change from baseline / baseline value) * 100%.</description>
          <population>Intent-to-Treat population. Only those participants available at the specified time points were analyzed.</population>
          <units>Percent change in VOI</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="43"/>
                <count group_id="O5" value="41"/>
                <count group_id="O6" value="49"/>
                <count group_id="O7" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" spread="4.19"/>
                    <measurement group_id="O2" value="0.85" spread="4.14"/>
                    <measurement group_id="O3" value="3.01" spread="5.18"/>
                    <measurement group_id="O4" value="3.58" spread="5.70"/>
                    <measurement group_id="O5" value="3.54" spread="5.64"/>
                    <measurement group_id="O6" value="5.39" spread="5.87"/>
                    <measurement group_id="O7" value="12.23" spread="8.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Month 12 in the Volumetric Integral, Cortical, and Trabecular Density (BMD) at the Hip as Measured by QCT Scans</title>
        <description>QCT is a three-dimensional non-projectional technique to quantify BMD with a number of advantages to other densitometric techniques. Cortical and trabecular bone can be separated, trabecular VOI are largely independent of degenerative changes in the spine and 3 dimensional geometric parameters can be determined. BMD as measured by QCT is a true density measured in mg/cm^3 in contrast to DXA Which determines an areal density measured in g/cm^2. Baseline values were assessed on Day 0. Percent change from Baseline was computed as (change from baseline / baseline value) * 100%.</description>
        <time_frame>Baseline (Day 0) and Month 12</time_frame>
        <population>Intent-to-Treat population. Only those participants available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received matching placebo OD (matching to ronacaleret tablet) and matching placebo OW (matching to Alendronate capsule) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
          </group>
          <group group_id="O2">
            <title>Ronacaleret, 100 mg Tablet, OD</title>
            <description>Participants received ronacaleret, 100 mg tablet, OD and matching placebo, OW (matching to Alendronate capsule) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
          </group>
          <group group_id="O3">
            <title>Ronacaleret, 200 mg Tablet, OD</title>
            <description>Participants received ronacaleret, 200 mg tablet, OD and matching placebo, OW (matching to Alendronate capsule) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
          </group>
          <group group_id="O4">
            <title>Ronacaleret, 300 mg Tablet, OD</title>
            <description>Participants received ronacaleret, 300 mg tablet, OD and matching placebo, OW (matching to Alendronate capsule) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
          </group>
          <group group_id="O5">
            <title>Ronacaleret, 400 mg Tablet, OD</title>
            <description>Participants received Ronacaleret, 400 mg tablet, OD and matching placebo, OW (matching to Alendronate capsule) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
          </group>
          <group group_id="O6">
            <title>Alendronate, 70 mg, Capsule, OW</title>
            <description>Participants received Alendronate, 70 mg, capsule, OW and matching placebo OD (matching to ronacaleret tablet) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
          </group>
          <group group_id="O7">
            <title>Teriparatide, 20 mcg, SC Injection, OD</title>
            <description>Participants received Teriparatide, 20 mcg, SC injection, OD for 12 months. Participants were supplied with elemental calcium 500-660mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Month 12 in the Volumetric Integral, Cortical, and Trabecular Density (BMD) at the Hip as Measured by QCT Scans</title>
          <description>QCT is a three-dimensional non-projectional technique to quantify BMD with a number of advantages to other densitometric techniques. Cortical and trabecular bone can be separated, trabecular VOI are largely independent of degenerative changes in the spine and 3 dimensional geometric parameters can be determined. BMD as measured by QCT is a true density measured in mg/cm^3 in contrast to DXA Which determines an areal density measured in g/cm^2. Baseline values were assessed on Day 0. Percent change from Baseline was computed as (change from baseline / baseline value) * 100%.</description>
          <population>Intent-to-Treat population. Only those participants available at the specified time points were analyzed.</population>
          <units>Percent change in BMD</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="47"/>
                <count group_id="O3" value="40"/>
                <count group_id="O4" value="39"/>
                <count group_id="O5" value="37"/>
                <count group_id="O6" value="45"/>
                <count group_id="O7" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Femur integral VOI BMD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" spread="2.78"/>
                    <measurement group_id="O2" value="-0.05" spread="2.67"/>
                    <measurement group_id="O3" value="-0.81" spread="2.80"/>
                    <measurement group_id="O4" value="-0.53" spread="2.18"/>
                    <measurement group_id="O5" value="-0.15" spread="2.98"/>
                    <measurement group_id="O6" value="2.70" spread="2.13"/>
                    <measurement group_id="O7" value="3.92" spread="2.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Femur trabecular VOI BMD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.36" spread="5.53"/>
                    <measurement group_id="O2" value="-0.40" spread="6.81"/>
                    <measurement group_id="O3" value="-2.16" spread="7.39"/>
                    <measurement group_id="O4" value="1.16" spread="5.06"/>
                    <measurement group_id="O5" value="2.81" spread="8.20"/>
                    <measurement group_id="O6" value="3.05" spread="5.92"/>
                    <measurement group_id="O7" value="13.19" spread="8.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Femur cortical VOI BMD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.11" spread="4.04"/>
                    <measurement group_id="O2" value="-0.32" spread="2.90"/>
                    <measurement group_id="O3" value="-1.46" spread="2.81"/>
                    <measurement group_id="O4" value="-1.06" spread="2.53"/>
                    <measurement group_id="O5" value="-1.79" spread="3.01"/>
                    <measurement group_id="O6" value="2.44" spread="3.13"/>
                    <measurement group_id="O7" value="0.22" spread="2.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neck integral VOI BMD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.10" spread="2.48"/>
                    <measurement group_id="O2" value="0.16" spread="2.83"/>
                    <measurement group_id="O3" value="-0.94" spread="3.34"/>
                    <measurement group_id="O4" value="-1.20" spread="2.99"/>
                    <measurement group_id="O5" value="-1.45" spread="3.22"/>
                    <measurement group_id="O6" value="1.65" spread="2.72"/>
                    <measurement group_id="O7" value="2.06" spread="3.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neck trabecular VOI BMD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.95" spread="7.44"/>
                    <measurement group_id="O2" value="-2.19" spread="7.91"/>
                    <measurement group_id="O3" value="-2.68" spread="6.14"/>
                    <measurement group_id="O4" value="1.35" spread="9.91"/>
                    <measurement group_id="O5" value="3.05" spread="11.18"/>
                    <measurement group_id="O6" value="2.77" spread="7.55"/>
                    <measurement group_id="O7" value="11.27" spread="10.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neck cortical VOI BMD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.23" spread="4.55"/>
                    <measurement group_id="O2" value="0.44" spread="4.16"/>
                    <measurement group_id="O3" value="-1.67" spread="3.95"/>
                    <measurement group_id="O4" value="-1.85" spread="3.89"/>
                    <measurement group_id="O5" value="-2.80" spread="4.55"/>
                    <measurement group_id="O6" value="1.10" spread="4.25"/>
                    <measurement group_id="O7" value="-0.69" spread="4.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trochanter integral VOI BMD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.58" spread="3.88"/>
                    <measurement group_id="O2" value="-0.16" spread="4.22"/>
                    <measurement group_id="O3" value="-1.53" spread="3.92"/>
                    <measurement group_id="O4" value="-1.16" spread="3.29"/>
                    <measurement group_id="O5" value="-0.98" spread="3.83"/>
                    <measurement group_id="O6" value="3.15" spread="3.27"/>
                    <measurement group_id="O7" value="4.96" spread="4.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trochanter trabecular VOI BMD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.62" spread="9.67"/>
                    <measurement group_id="O2" value="-1.34" spread="13.50"/>
                    <measurement group_id="O3" value="-2.54" spread="11.05"/>
                    <measurement group_id="O4" value="2.12" spread="8.82"/>
                    <measurement group_id="O5" value="2.10" spread="10.66"/>
                    <measurement group_id="O6" value="3.55" spread="7.55"/>
                    <measurement group_id="O7" value="14.12" spread="14.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trochanter cortical VOI BMD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.56" spread="5.29"/>
                    <measurement group_id="O2" value="-0.70" spread="4.08"/>
                    <measurement group_id="O3" value="-1.53" spread="3.60"/>
                    <measurement group_id="O4" value="-1.48" spread="3.53"/>
                    <measurement group_id="O5" value="-2.59" spread="4.04"/>
                    <measurement group_id="O6" value="3.33" spread="3.57"/>
                    <measurement group_id="O7" value="1.99" spread="4.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to Month 12 in Cortical Thickness at the Hip as Measured by QCT Scans</title>
        <description>Percent change in thickness of femur neck cortical VOI thickness and trochanter cortical VOI thickness were at Month 12 measured by QCT were reported. Assessments performed on Day 0 were considered as Baseline. Percent change from Baseline was computed as (change from baseline / baseline value) * 100%.</description>
        <time_frame>Baseline (Day 0) and Month 12</time_frame>
        <population>Intent-to-Treat population. Only those participants available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received matching placebo OD (matching to ronacaleret tablet) and matching placebo OW (matching to Alendronate capsule) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
          </group>
          <group group_id="O2">
            <title>Ronacaleret, 100 mg Tablet, OD</title>
            <description>Participants received ronacaleret, 100 mg tablet, OD and matching placebo, OW (matching to Alendronate capsule) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
          </group>
          <group group_id="O3">
            <title>Ronacaleret, 200 mg Tablet, OD</title>
            <description>Participants received ronacaleret, 200 mg tablet, OD and matching placebo, OW (matching to Alendronate capsule) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
          </group>
          <group group_id="O4">
            <title>Ronacaleret, 300 mg Tablet, OD</title>
            <description>Participants received ronacaleret, 300 mg tablet, OD and matching placebo, OW (matching to Alendronate capsule) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
          </group>
          <group group_id="O5">
            <title>Ronacaleret, 400 mg Tablet, OD</title>
            <description>Participants received Ronacaleret, 400 mg tablet, OD and matching placebo, OW (matching to Alendronate capsule) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
          </group>
          <group group_id="O6">
            <title>Alendronate, 70 mg, Capsule, OW</title>
            <description>Participants received Alendronate, 70 mg, capsule, OW and matching placebo OD (matching to ronacaleret tablet) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
          </group>
          <group group_id="O7">
            <title>Teriparatide, 20 mcg, SC Injection, OD</title>
            <description>Participants received Teriparatide, 20 mcg, SC injection, OD for 12 months. Participants were supplied with elemental calcium 500-660mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to Month 12 in Cortical Thickness at the Hip as Measured by QCT Scans</title>
          <description>Percent change in thickness of femur neck cortical VOI thickness and trochanter cortical VOI thickness were at Month 12 measured by QCT were reported. Assessments performed on Day 0 were considered as Baseline. Percent change from Baseline was computed as (change from baseline / baseline value) * 100%.</description>
          <population>Intent-to-Treat population. Only those participants available at the specified time points were analyzed.</population>
          <units>Percent change in cortical thickness</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="47"/>
                <count group_id="O3" value="40"/>
                <count group_id="O4" value="39"/>
                <count group_id="O5" value="37"/>
                <count group_id="O6" value="45"/>
                <count group_id="O7" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Neck cortical VOI Thickness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.85" spread="7.09"/>
                    <measurement group_id="O2" value="-0.13" spread="5.98"/>
                    <measurement group_id="O3" value="1.12" spread="5.75"/>
                    <measurement group_id="O4" value="-0.88" spread="4.73"/>
                    <measurement group_id="O5" value="0.32" spread="4.93"/>
                    <measurement group_id="O6" value="-0.13" spread="5.98"/>
                    <measurement group_id="O7" value="0.39" spread="4.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trochanter cortical VOI Thickness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.00" spread="5.85"/>
                    <measurement group_id="O2" value="0.76" spread="4.40"/>
                    <measurement group_id="O3" value="1.01" spread="5.15"/>
                    <measurement group_id="O4" value="-0.82" spread="3.65"/>
                    <measurement group_id="O5" value="1.60" spread="3.70"/>
                    <measurement group_id="O6" value="0.81" spread="5.39"/>
                    <measurement group_id="O7" value="0.76" spread="2.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Biochemical Markers of Bone Turnover: Levels of C-terminal Telopeptide α1 Chain of Type 1 Collagen (CTX1)</title>
        <description>Blood samples were collected at Baseline (Day 0), Week 4, Month 3, 6, and 12 for measurement of CTX1.</description>
        <time_frame>Baseline (Day 0), Week 4, Month 3, 6, and 12</time_frame>
        <population>Intent-to-Treat population. Only those participants available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received matching placebo OD (matching to ronacaleret tablet) and matching placebo OW (matching to Alendronate capsule) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
          </group>
          <group group_id="O2">
            <title>Ronacaleret, 100 mg Tablet, OD</title>
            <description>Participants received ronacaleret, 100 mg tablet, OD and matching placebo, OW (matching to Alendronate capsule) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
          </group>
          <group group_id="O3">
            <title>Ronacaleret, 200 mg Tablet, OD</title>
            <description>Participants received ronacaleret, 200 mg tablet, OD and matching placebo, OW (matching to Alendronate capsule) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
          </group>
          <group group_id="O4">
            <title>Ronacaleret, 300 mg Tablet, OD</title>
            <description>Participants received ronacaleret, 300 mg tablet, OD and matching placebo, OW (matching to Alendronate capsule) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
          </group>
          <group group_id="O5">
            <title>Ronacaleret, 400 mg Tablet, OD</title>
            <description>Participants received Ronacaleret, 400 mg tablet, OD and matching placebo, OW (matching to Alendronate capsule) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
          </group>
          <group group_id="O6">
            <title>Alendronate, 70 mg, Capsule, OW</title>
            <description>Participants received Alendronate, 70 mg, capsule, OW and matching placebo OD (matching to ronacaleret tablet) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
          </group>
          <group group_id="O7">
            <title>Teriparatide, 20 mcg, SC Injection, OD</title>
            <description>Participants received Teriparatide, 20 mcg, SC injection, OD for 12 months. Participants were supplied with elemental calcium 500-660mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Biochemical Markers of Bone Turnover: Levels of C-terminal Telopeptide α1 Chain of Type 1 Collagen (CTX1)</title>
          <description>Blood samples were collected at Baseline (Day 0), Week 4, Month 3, 6, and 12 for measurement of CTX1.</description>
          <population>Intent-to-Treat population. Only those participants available at the specified time points were analyzed.</population>
          <units>nanogram per litre (ng/L)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="87"/>
                <count group_id="O3" value="82"/>
                <count group_id="O4" value="88"/>
                <count group_id="O5" value="87"/>
                <count group_id="O6" value="89"/>
                <count group_id="O7" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="88"/>
                    <count group_id="O2" value="82"/>
                    <count group_id="O3" value="81"/>
                    <count group_id="O4" value="87"/>
                    <count group_id="O5" value="84"/>
                    <count group_id="O6" value="87"/>
                    <count group_id="O7" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="625.2" spread="1.05"/>
                    <measurement group_id="O2" value="635.3" spread="1.05"/>
                    <measurement group_id="O3" value="632.0" spread="1.05"/>
                    <measurement group_id="O4" value="587.9" spread="1.05"/>
                    <measurement group_id="O5" value="645.5" spread="1.05"/>
                    <measurement group_id="O6" value="630.4" spread="1.05"/>
                    <measurement group_id="O7" value="564.0" spread="1.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline, Placebo contrast</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="82"/>
                    <count group_id="O3" value="81"/>
                    <count group_id="O4" value="87"/>
                    <count group_id="O5" value="84"/>
                    <count group_id="O6" value="87"/>
                    <count group_id="O7" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="1.02" spread="1.07"/>
                    <measurement group_id="O3" value="1.01" spread="1.07"/>
                    <measurement group_id="O4" value="0.94" spread="1.07"/>
                    <measurement group_id="O5" value="1.03" spread="1.07"/>
                    <measurement group_id="O6" value="1.01" spread="1.07"/>
                    <measurement group_id="O7" value="0.90" spread="1.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="78"/>
                    <count group_id="O3" value="76"/>
                    <count group_id="O4" value="83"/>
                    <count group_id="O5" value="78"/>
                    <count group_id="O6" value="63"/>
                    <count group_id="O7" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="530.7" spread="1.05"/>
                    <measurement group_id="O2" value="515.2" spread="1.05"/>
                    <measurement group_id="O3" value="525.4" spread="1.05"/>
                    <measurement group_id="O4" value="506.1" spread="1.05"/>
                    <measurement group_id="O5" value="529.2" spread="1.05"/>
                    <measurement group_id="O6" value="288.0" spread="1.06"/>
                    <measurement group_id="O7" value="576.1" spread="1.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4, Placebo contrast</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="78"/>
                    <count group_id="O3" value="76"/>
                    <count group_id="O4" value="83"/>
                    <count group_id="O5" value="78"/>
                    <count group_id="O6" value="63"/>
                    <count group_id="O7" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.97" spread="1.08"/>
                    <measurement group_id="O3" value="0.99" spread="1.08"/>
                    <measurement group_id="O4" value="0.95" spread="1.08"/>
                    <measurement group_id="O5" value="1.00" spread="1.08"/>
                    <measurement group_id="O6" value="0.54" spread="1.08"/>
                    <measurement group_id="O7" value="1.09" spread="1.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="73"/>
                    <count group_id="O3" value="71"/>
                    <count group_id="O4" value="75"/>
                    <count group_id="O5" value="72"/>
                    <count group_id="O6" value="49"/>
                    <count group_id="O7" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="523.5" spread="1.05"/>
                    <measurement group_id="O2" value="598.5" spread="1.06"/>
                    <measurement group_id="O3" value="688.9" spread="1.06"/>
                    <measurement group_id="O4" value="723.2" spread="1.05"/>
                    <measurement group_id="O5" value="818.9" spread="1.06"/>
                    <measurement group_id="O6" value="257.1" spread="1.06"/>
                    <measurement group_id="O7" value="864.1" spread="1.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3, Placebo contrast</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="73"/>
                    <count group_id="O3" value="71"/>
                    <count group_id="O4" value="75"/>
                    <count group_id="O5" value="72"/>
                    <count group_id="O6" value="49"/>
                    <count group_id="O7" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="1.14" spread="1.08"/>
                    <measurement group_id="O3" value="1.32" spread="1.08"/>
                    <measurement group_id="O4" value="1.38" spread="1.08"/>
                    <measurement group_id="O5" value="1.56" spread="1.08"/>
                    <measurement group_id="O6" value="0.49" spread="1.08"/>
                    <measurement group_id="O7" value="1.65" spread="1.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="70"/>
                    <count group_id="O3" value="66"/>
                    <count group_id="O4" value="73"/>
                    <count group_id="O5" value="70"/>
                    <count group_id="O6" value="34"/>
                    <count group_id="O7" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="517.6" spread="1.06"/>
                    <measurement group_id="O2" value="648.2" spread="1.06"/>
                    <measurement group_id="O3" value="777.1" spread="1.06"/>
                    <measurement group_id="O4" value="859.6" spread="1.06"/>
                    <measurement group_id="O5" value="964.3" spread="1.06"/>
                    <measurement group_id="O6" value="235.9" spread="1.07"/>
                    <measurement group_id="O7" value="1112" spread="1.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6, Placebo contrast</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="70"/>
                    <count group_id="O3" value="66"/>
                    <count group_id="O4" value="73"/>
                    <count group_id="O5" value="70"/>
                    <count group_id="O6" value="34"/>
                    <count group_id="O7" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="1.25" spread="1.08"/>
                    <measurement group_id="O3" value="1.50" spread="1.08"/>
                    <measurement group_id="O4" value="1.66" spread="1.08"/>
                    <measurement group_id="O5" value="1.86" spread="1.08"/>
                    <measurement group_id="O6" value="0.46" spread="1.09"/>
                    <measurement group_id="O7" value="2.15" spread="1.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="50"/>
                    <count group_id="O2" value="44"/>
                    <count group_id="O3" value="49"/>
                    <count group_id="O4" value="40"/>
                    <count group_id="O5" value="49"/>
                    <count group_id="O6" value="50"/>
                    <count group_id="O7" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="525.1" spread="1.08"/>
                    <measurement group_id="O2" value="695.2" spread="1.08"/>
                    <measurement group_id="O3" value="806.1" spread="1.08"/>
                    <measurement group_id="O4" value="852.8" spread="1.08"/>
                    <measurement group_id="O5" value="991.9" spread="1.08"/>
                    <measurement group_id="O6" value="158.3" spread="1.08"/>
                    <measurement group_id="O7" value="1071" spread="1.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12, Placebo contrast</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="44"/>
                    <count group_id="O3" value="49"/>
                    <count group_id="O4" value="40"/>
                    <count group_id="O5" value="49"/>
                    <count group_id="O6" value="50"/>
                    <count group_id="O7" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="1.32" spread="1.12"/>
                    <measurement group_id="O3" value="1.54" spread="1.11"/>
                    <measurement group_id="O4" value="1.62" spread="1.12"/>
                    <measurement group_id="O5" value="1.89" spread="1.11"/>
                    <measurement group_id="O6" value="0.30" spread="1.11"/>
                    <measurement group_id="O7" value="2.04" spread="1.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Biochemical Markers of Bone Turnover: Procollagen Type 1 N-terminal Propeptide (P1NP)</title>
        <description>Blood samples were collected at Baseline (Day 0), Week 4, Month 3, 6, and 12 for measurement of P1NP.</description>
        <time_frame>Baseline (Day 0), Week 4, Month 3, 6, and 12</time_frame>
        <population>Intent to treat population. Only those participants available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received matching placebo OD (matching to ronacaleret tablet) and matching placebo OW (matching to Alendronate capsule) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
          </group>
          <group group_id="O2">
            <title>Ronacaleret, 100 mg Tablet, OD</title>
            <description>Participants received ronacaleret, 100 mg tablet, OD and matching placebo, OW (matching to Alendronate capsule) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
          </group>
          <group group_id="O3">
            <title>Ronacaleret, 200 mg Tablet, OD</title>
            <description>Participants received ronacaleret, 200 mg tablet, OD and matching placebo, OW (matching to Alendronate capsule) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
          </group>
          <group group_id="O4">
            <title>Ronacaleret, 300 mg Tablet, OD</title>
            <description>Participants received ronacaleret, 300 mg tablet, OD and matching placebo, OW (matching to Alendronate capsule) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
          </group>
          <group group_id="O5">
            <title>Ronacaleret, 400 mg Tablet, OD</title>
            <description>Participants received Ronacaleret, 400 mg tablet, OD and matching placebo, OW (matching to Alendronate capsule) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
          </group>
          <group group_id="O6">
            <title>Alendronate, 70 mg, Capsule, OW</title>
            <description>Participants received Alendronate, 70 mg, capsule, OW and matching placebo OD (matching to ronacaleret tablet) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
          </group>
          <group group_id="O7">
            <title>Teriparatide, 20 mcg, SC Injection, OD</title>
            <description>Participants received Teriparatide, 20 mcg, SC injection, OD for 12 months. Participants were supplied with elemental calcium 500-660mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Biochemical Markers of Bone Turnover: Procollagen Type 1 N-terminal Propeptide (P1NP)</title>
          <description>Blood samples were collected at Baseline (Day 0), Week 4, Month 3, 6, and 12 for measurement of P1NP.</description>
          <population>Intent to treat population. Only those participants available at the specified time points were analyzed.</population>
          <units>Microgram per Litre (mcg/L)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="87"/>
                <count group_id="O3" value="82"/>
                <count group_id="O4" value="88"/>
                <count group_id="O5" value="87"/>
                <count group_id="O6" value="89"/>
                <count group_id="O7" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="86"/>
                    <count group_id="O2" value="83"/>
                    <count group_id="O3" value="81"/>
                    <count group_id="O4" value="87"/>
                    <count group_id="O5" value="83"/>
                    <count group_id="O6" value="88"/>
                    <count group_id="O7" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.66" spread="1.05"/>
                    <measurement group_id="O2" value="45.59" spread="1.05"/>
                    <measurement group_id="O3" value="47.70" spread="1.05"/>
                    <measurement group_id="O4" value="46.62" spread="1.05"/>
                    <measurement group_id="O5" value="46.19" spread="1.05"/>
                    <measurement group_id="O6" value="47.71" spread="1.05"/>
                    <measurement group_id="O7" value="48.57" spread="1.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline, Placebo contrast</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="83"/>
                    <count group_id="O3" value="81"/>
                    <count group_id="O4" value="87"/>
                    <count group_id="O5" value="83"/>
                    <count group_id="O6" value="88"/>
                    <count group_id="O7" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.96" spread="1.07"/>
                    <measurement group_id="O3" value="1.00" spread="1.07"/>
                    <measurement group_id="O4" value="0.98" spread="1.07"/>
                    <measurement group_id="O5" value="0.97" spread="1.07"/>
                    <measurement group_id="O6" value="1.00" spread="1.07"/>
                    <measurement group_id="O7" value="1.02" spread="1.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="80"/>
                    <count group_id="O2" value="78"/>
                    <count group_id="O3" value="75"/>
                    <count group_id="O4" value="85"/>
                    <count group_id="O5" value="79"/>
                    <count group_id="O6" value="81"/>
                    <count group_id="O7" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.32" spread="1.05"/>
                    <measurement group_id="O2" value="49.67" spread="1.05"/>
                    <measurement group_id="O3" value="57.36" spread="1.05"/>
                    <measurement group_id="O4" value="60.27" spread="1.05"/>
                    <measurement group_id="O5" value="63.46" spread="1.05"/>
                    <measurement group_id="O6" value="43.66" spread="1.05"/>
                    <measurement group_id="O7" value="92.74" spread="1.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4, Placebo contrast</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="78"/>
                    <count group_id="O3" value="75"/>
                    <count group_id="O4" value="85"/>
                    <count group_id="O5" value="79"/>
                    <count group_id="O6" value="81"/>
                    <count group_id="O7" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="1.10" spread="1.07"/>
                    <measurement group_id="O3" value="1.27" spread="1.07"/>
                    <measurement group_id="O4" value="1.33" spread="1.07"/>
                    <measurement group_id="O5" value="1.40" spread="1.07"/>
                    <measurement group_id="O6" value="0.96" spread="1.07"/>
                    <measurement group_id="O7" value="2.05" spread="1.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="77"/>
                    <count group_id="O2" value="72"/>
                    <count group_id="O3" value="72"/>
                    <count group_id="O4" value="76"/>
                    <count group_id="O5" value="73"/>
                    <count group_id="O6" value="79"/>
                    <count group_id="O7" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.53" spread="1.05"/>
                    <measurement group_id="O2" value="49.99" spread="1.05"/>
                    <measurement group_id="O3" value="65.21" spread="1.05"/>
                    <measurement group_id="O4" value="73.68" spread="1.05"/>
                    <measurement group_id="O5" value="86.84" spread="1.05"/>
                    <measurement group_id="O6" value="20.15" spread="1.05"/>
                    <measurement group_id="O7" value="99.74" spread="1.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3, Placebo contrast</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="72"/>
                    <count group_id="O3" value="72"/>
                    <count group_id="O4" value="76"/>
                    <count group_id="O5" value="73"/>
                    <count group_id="O6" value="79"/>
                    <count group_id="O7" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="1.26" spread="1.08"/>
                    <measurement group_id="O3" value="1.65" spread="1.08"/>
                    <measurement group_id="O4" value="1.86" spread="1.08"/>
                    <measurement group_id="O5" value="2.20" spread="1.08"/>
                    <measurement group_id="O6" value="0.51" spread="1.07"/>
                    <measurement group_id="O7" value="2.52" spread="1.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="70"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="72"/>
                    <count group_id="O5" value="70"/>
                    <count group_id="O6" value="74"/>
                    <count group_id="O7" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.41" spread="1.05"/>
                    <measurement group_id="O2" value="56.37" spread="1.05"/>
                    <measurement group_id="O3" value="75.73" spread="1.06"/>
                    <measurement group_id="O4" value="90.55" spread="1.05"/>
                    <measurement group_id="O5" value="104.6" spread="1.05"/>
                    <measurement group_id="O6" value="16.41" spread="1.05"/>
                    <measurement group_id="O7" value="117.8" spread="1.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6, Placebo contrast</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="70"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="72"/>
                    <count group_id="O5" value="70"/>
                    <count group_id="O6" value="74"/>
                    <count group_id="O7" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="1.47" spread="1.08"/>
                    <measurement group_id="O3" value="1.97" spread="1.08"/>
                    <measurement group_id="O4" value="2.36" spread="1.08"/>
                    <measurement group_id="O5" value="2.72" spread="1.08"/>
                    <measurement group_id="O6" value="0.43" spread="1.08"/>
                    <measurement group_id="O7" value="3.07" spread="1.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="50"/>
                    <count group_id="O2" value="44"/>
                    <count group_id="O3" value="50"/>
                    <count group_id="O4" value="40"/>
                    <count group_id="O5" value="49"/>
                    <count group_id="O6" value="51"/>
                    <count group_id="O7" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.74" spread="1.05"/>
                    <measurement group_id="O2" value="61.43" spread="1.05"/>
                    <measurement group_id="O3" value="82.69" spread="1.05"/>
                    <measurement group_id="O4" value="98.04" spread="1.05"/>
                    <measurement group_id="O5" value="112.6" spread="1.05"/>
                    <measurement group_id="O6" value="16.98" spread="1.05"/>
                    <measurement group_id="O7" value="119.0" spread="1.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12, Placebo contrast</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="44"/>
                    <count group_id="O3" value="50"/>
                    <count group_id="O4" value="40"/>
                    <count group_id="O5" value="49"/>
                    <count group_id="O6" value="51"/>
                    <count group_id="O7" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="1.51" spread="1.08"/>
                    <measurement group_id="O3" value="2.03" spread="1.08"/>
                    <measurement group_id="O4" value="2.41" spread="1.08"/>
                    <measurement group_id="O5" value="2.76" spread="1.08"/>
                    <measurement group_id="O6" value="0.42" spread="1.08"/>
                    <measurement group_id="O7" value="2.92" spread="1.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Biochemical Markers of Bone Turnover: Bone Specific Alkaline Phosphatase (BALP)</title>
        <description>Blood samples were collected at Baseline (Day 0), Week 4, Month 3, 6, and 12 for measurement of BALP.</description>
        <time_frame>Baseline (Day 0), Week 4, Month 3, 6, and 12</time_frame>
        <population>Intent-to-Treat population. Only those participants available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received matching placebo OD (matching to ronacaleret tablet) and matching placebo OW (matching to Alendronate capsule) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
          </group>
          <group group_id="O2">
            <title>Ronacaleret, 100 mg Tablet, OD</title>
            <description>Participants received ronacaleret, 100 mg tablet, OD and matching placebo, OW (matching to Alendronate capsule) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
          </group>
          <group group_id="O3">
            <title>Ronacaleret, 200 mg Tablet, OD</title>
            <description>Participants received ronacaleret, 200 mg tablet, OD and matching placebo, OW (matching to Alendronate capsule) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
          </group>
          <group group_id="O4">
            <title>Ronacaleret, 300 mg Tablet, OD</title>
            <description>Participants received ronacaleret, 300 mg tablet, OD and matching placebo, OW (matching to Alendronate capsule) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
          </group>
          <group group_id="O5">
            <title>Ronacaleret, 400 mg Tablet, OD</title>
            <description>Participants received Ronacaleret, 400 mg tablet, OD and matching placebo, OW (matching to Alendronate capsule) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
          </group>
          <group group_id="O6">
            <title>Alendronate, 70 mg, Capsule, OW</title>
            <description>Participants received Alendronate, 70 mg, capsule, OW and matching placebo OD (matching to ronacaleret tablet) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
          </group>
          <group group_id="O7">
            <title>Teriparatide, 20 mcg, SC Injection, OD</title>
            <description>Participants received Teriparatide, 20 mcg, SC injection, OD for 12 months. Participants were supplied with elemental calcium 500-660mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Biochemical Markers of Bone Turnover: Bone Specific Alkaline Phosphatase (BALP)</title>
          <description>Blood samples were collected at Baseline (Day 0), Week 4, Month 3, 6, and 12 for measurement of BALP.</description>
          <population>Intent-to-Treat population. Only those participants available at the specified time points were analyzed.</population>
          <units>mcg/L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="87"/>
                <count group_id="O3" value="82"/>
                <count group_id="O4" value="88"/>
                <count group_id="O5" value="87"/>
                <count group_id="O6" value="89"/>
                <count group_id="O7" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="89"/>
                    <count group_id="O2" value="84"/>
                    <count group_id="O3" value="81"/>
                    <count group_id="O4" value="88"/>
                    <count group_id="O5" value="86"/>
                    <count group_id="O6" value="89"/>
                    <count group_id="O7" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.46" spread="1.04"/>
                    <measurement group_id="O2" value="14.96" spread="1.04"/>
                    <measurement group_id="O3" value="14.24" spread="1.04"/>
                    <measurement group_id="O4" value="15.06" spread="1.04"/>
                    <measurement group_id="O5" value="14.12" spread="1.04"/>
                    <measurement group_id="O6" value="14.31" spread="1.04"/>
                    <measurement group_id="O7" value="14.50" spread="1.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline, Placebo contrast</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="84"/>
                    <count group_id="O3" value="81"/>
                    <count group_id="O4" value="88"/>
                    <count group_id="O5" value="86"/>
                    <count group_id="O6" value="89"/>
                    <count group_id="O7" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="1.03" spread="1.05"/>
                    <measurement group_id="O3" value="0.98" spread="1.05"/>
                    <measurement group_id="O4" value="1.04" spread="1.05"/>
                    <measurement group_id="O5" value="0.98" spread="1.05"/>
                    <measurement group_id="O6" value="0.99" spread="1.05"/>
                    <measurement group_id="O7" value="1.00" spread="1.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="79"/>
                    <count group_id="O2" value="79"/>
                    <count group_id="O3" value="76"/>
                    <count group_id="O4" value="85"/>
                    <count group_id="O5" value="79"/>
                    <count group_id="O6" value="83"/>
                    <count group_id="O7" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.02" spread="1.04"/>
                    <measurement group_id="O2" value="14.72" spread="1.04"/>
                    <measurement group_id="O3" value="14.51" spread="1.04"/>
                    <measurement group_id="O4" value="15.97" spread="1.04"/>
                    <measurement group_id="O5" value="15.72" spread="1.04"/>
                    <measurement group_id="O6" value="13.68" spread="1.04"/>
                    <measurement group_id="O7" value="16.19" spread="1.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4, Placebo contrast</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="79"/>
                    <count group_id="O3" value="76"/>
                    <count group_id="O4" value="85"/>
                    <count group_id="O5" value="79"/>
                    <count group_id="O6" value="83"/>
                    <count group_id="O7" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="1.05" spread="1.05"/>
                    <measurement group_id="O3" value="1.03" spread="1.06"/>
                    <measurement group_id="O4" value="1.14" spread="1.05"/>
                    <measurement group_id="O5" value="1.12" spread="1.05"/>
                    <measurement group_id="O6" value="0.98" spread="1.05"/>
                    <measurement group_id="O7" value="1.15" spread="1.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="77"/>
                    <count group_id="O2" value="73"/>
                    <count group_id="O3" value="71"/>
                    <count group_id="O4" value="75"/>
                    <count group_id="O5" value="73"/>
                    <count group_id="O6" value="78"/>
                    <count group_id="O7" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.66" spread="1.04"/>
                    <measurement group_id="O2" value="15.23" spread="1.04"/>
                    <measurement group_id="O3" value="15.44" spread="1.04"/>
                    <measurement group_id="O4" value="18.77" spread="1.04"/>
                    <measurement group_id="O5" value="17.85" spread="1.04"/>
                    <measurement group_id="O6" value="9.44" spread="1.04"/>
                    <measurement group_id="O7" value="16.53" spread="1.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3, Placebo contrast</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="73"/>
                    <count group_id="O3" value="71"/>
                    <count group_id="O4" value="75"/>
                    <count group_id="O5" value="73"/>
                    <count group_id="O6" value="78"/>
                    <count group_id="O7" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="1.20" spread="1.06"/>
                    <measurement group_id="O3" value="1.22" spread="1.06"/>
                    <measurement group_id="O4" value="1.48" spread="1.06"/>
                    <measurement group_id="O5" value="1.41" spread="1.06"/>
                    <measurement group_id="O6" value="0.75" spread="1.06"/>
                    <measurement group_id="O7" value="1.31" spread="1.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="71"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="73"/>
                    <count group_id="O5" value="70"/>
                    <count group_id="O6" value="74"/>
                    <count group_id="O7" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.81" spread="1.04"/>
                    <measurement group_id="O2" value="16.31" spread="1.04"/>
                    <measurement group_id="O3" value="17.43" spread="1.04"/>
                    <measurement group_id="O4" value="22.18" spread="1.04"/>
                    <measurement group_id="O5" value="21.47" spread="1.04"/>
                    <measurement group_id="O6" value="8.36" spread="1.04"/>
                    <measurement group_id="O7" value="17.63" spread="1.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6, Placebo contrast</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="71"/>
                    <count group_id="O3" value="67"/>
                    <count group_id="O4" value="73"/>
                    <count group_id="O5" value="70"/>
                    <count group_id="O6" value="74"/>
                    <count group_id="O7" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="1.27" spread="1.06"/>
                    <measurement group_id="O3" value="1.36" spread="1.06"/>
                    <measurement group_id="O4" value="1.73" spread="1.06"/>
                    <measurement group_id="O5" value="1.68" spread="1.06"/>
                    <measurement group_id="O6" value="0.65" spread="1.06"/>
                    <measurement group_id="O7" value="1.38" spread="1.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="50"/>
                    <count group_id="O2" value="44"/>
                    <count group_id="O3" value="50"/>
                    <count group_id="O4" value="40"/>
                    <count group_id="O5" value="48"/>
                    <count group_id="O6" value="50"/>
                    <count group_id="O7" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.25" spread="1.04"/>
                    <measurement group_id="O2" value="16.64" spread="1.04"/>
                    <measurement group_id="O3" value="18.80" spread="1.04"/>
                    <measurement group_id="O4" value="23.36" spread="1.04"/>
                    <measurement group_id="O5" value="23.28" spread="1.04"/>
                    <measurement group_id="O6" value="8.42" spread="1.04"/>
                    <measurement group_id="O7" value="19.08" spread="1.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12, Placebo contrast</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="44"/>
                    <count group_id="O3" value="50"/>
                    <count group_id="O4" value="40"/>
                    <count group_id="O5" value="48"/>
                    <count group_id="O6" value="50"/>
                    <count group_id="O7" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="1.26" spread="1.06"/>
                    <measurement group_id="O3" value="1.42" spread="1.06"/>
                    <measurement group_id="O4" value="1.76" spread="1.06"/>
                    <measurement group_id="O5" value="1.76" spread="1.06"/>
                    <measurement group_id="O6" value="0.64" spread="1.06"/>
                    <measurement group_id="O7" value="1.44" spread="1.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Blood Concentrations of Ronacaleret</title>
        <description>Blood samples were collected and analyzed for concentrations of ronacaleret. The individual blood concentration-time data from the intensive PK-PD subgroup of participants were analyzed by standard noncompartmental methods. Blood concentrations of ronacaleret were reported.</description>
        <time_frame>Pre-dose (0.0 hour [h]) and 12 h post dose at Week 4, 20, 40 min, 1, 1.5, 2.0, 2.5, 3.0, 4.0, 6.0, 8.0, 1-4, 8-12, and 24 h at Month 3, 6 and 12</time_frame>
        <population>Pharmacokinetic Concentration Population comprised of any Intent-to-Treat participants for whom a SB-751689 pharmacokinetic blood sample was obtained and analyzed. Only those participants available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Ronacaleret, 100 mg Tablet, OD</title>
            <description>Participants received ronacaleret, 100 mg tablet, OD and matching placebo, OW (matching to Alendronate capsule) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
          </group>
          <group group_id="O2">
            <title>Ronacaleret, 200 mg Tablet, OD</title>
            <description>Participants received ronacaleret, 200 mg tablet, OD and matching placebo, OW (matching to Alendronate capsule) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
          </group>
          <group group_id="O3">
            <title>Ronacaleret, 300 mg Tablet, OD</title>
            <description>Participants received ronacaleret, 300 mg tablet, OD and matching placebo, OW (matching to Alendronate capsule) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
          </group>
          <group group_id="O4">
            <title>Ronacaleret, 400 mg Tablet, OD</title>
            <description>Participants received Ronacaleret, 400 mg tablet, OD and matching placebo, OW (matching to Alendronate capsule) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Blood Concentrations of Ronacaleret</title>
          <description>Blood samples were collected and analyzed for concentrations of ronacaleret. The individual blood concentration-time data from the intensive PK-PD subgroup of participants were analyzed by standard noncompartmental methods. Blood concentrations of ronacaleret were reported.</description>
          <population>Pharmacokinetic Concentration Population comprised of any Intent-to-Treat participants for whom a SB-751689 pharmacokinetic blood sample was obtained and analyzed. Only those participants available at the specified time points were analyzed.</population>
          <units>nanograms per millilitre (ng/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="74"/>
                <count group_id="O3" value="80"/>
                <count group_id="O4" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4, Pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="65"/>
                    <count group_id="O3" value="73"/>
                    <count group_id="O4" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.22" spread="127.438"/>
                    <measurement group_id="O2" value="37.24" spread="36.203"/>
                    <measurement group_id="O3" value="85.44" spread="158.849"/>
                    <measurement group_id="O4" value="79.40" spread="74.083"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4, 8-12 h post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="66"/>
                    <count group_id="O2" value="64"/>
                    <count group_id="O3" value="72"/>
                    <count group_id="O4" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="204.82" spread="183.245"/>
                    <measurement group_id="O2" value="328.33" spread="222.061"/>
                    <measurement group_id="O3" value="581.08" spread="360.031"/>
                    <measurement group_id="O4" value="685.14" spread="450.467"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6, Pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="66"/>
                    <count group_id="O2" value="61"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="67"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.37" spread="19.769"/>
                    <measurement group_id="O2" value="65.94" spread="214.325"/>
                    <measurement group_id="O3" value="74.12" spread="146.094"/>
                    <measurement group_id="O4" value="117.94" spread="288.413"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6, 1-4 h post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="49"/>
                    <count group_id="O2" value="45"/>
                    <count group_id="O3" value="51"/>
                    <count group_id="O4" value="53"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="644.90" spread="408.282"/>
                    <measurement group_id="O2" value="1308.35" spread="943.397"/>
                    <measurement group_id="O3" value="1610.74" spread="1016.608"/>
                    <measurement group_id="O4" value="2054.71" spread="1499.079"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6, 8-12 h post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="52"/>
                    <count group_id="O2" value="45"/>
                    <count group_id="O3" value="53"/>
                    <count group_id="O4" value="54"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="186.69" spread="101.326"/>
                    <measurement group_id="O2" value="385.03" spread="284.963"/>
                    <measurement group_id="O3" value="576.35" spread="382.494"/>
                    <measurement group_id="O4" value="796.99" spread="640.016"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6, 24 h post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="186.21" spread="151.855"/>
                    <measurement group_id="O2" value="290.74" spread="125.486"/>
                    <measurement group_id="O3" value="578.63" spread="398.915"/>
                    <measurement group_id="O4" value="473.41" spread="237.671"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12, Pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="38"/>
                    <count group_id="O4" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.68" spread="15.971"/>
                    <measurement group_id="O2" value="33.47" spread="26.747"/>
                    <measurement group_id="O3" value="147.63" spread="370.860"/>
                    <measurement group_id="O4" value="114.83" spread="179.448"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12, 1-4 h post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="28"/>
                    <count group_id="O2" value="28"/>
                    <count group_id="O3" value="28"/>
                    <count group_id="O4" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="779.92" spread="465.356"/>
                    <measurement group_id="O2" value="999.63" spread="659.880"/>
                    <measurement group_id="O3" value="1819.53" spread="1021.984"/>
                    <measurement group_id="O4" value="2128.24" spread="1549.003"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12, 8-12 h post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="30"/>
                    <count group_id="O2" value="28"/>
                    <count group_id="O3" value="27"/>
                    <count group_id="O4" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="203.39" spread="124.866"/>
                    <measurement group_id="O2" value="262.20" spread="137.152"/>
                    <measurement group_id="O3" value="651.95" spread="391.752"/>
                    <measurement group_id="O4" value="740.18" spread="679.348"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12, 24 h post dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="187.23" spread="100.001"/>
                    <measurement group_id="O2" value="297.20" spread="146.806"/>
                    <measurement group_id="O3" value="626.72" spread="231.777"/>
                    <measurement group_id="O4" value="512.65" spread="314.692"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Concentration-time Curve Over the Dosing Interval (AUC 0-t) and Area Under the Concentration-time Curve Over the Dosing Interval (AUC 0-tau) of Ronacaleret</title>
        <description>Blood samples were collected and analyzed for concentrations of ronacaleret. The individual blood concentration-time data from the intensive pharmacokinetic and pharmacodynamics subgroup of participants were analyzed by standard noncompartmental methods. Blood samples were collected and analyzed for concentrations of ronacaleret. The individual blood concentration-time data from the intensive PK-PD subgroup of participants were analyzed by standard noncompartmental methods. Following log transformation, AUC(0-t) and AUC(0-τ) of ronacaleret were separately analyzed by ANOVA using mixed effects model, fitting treatment and country/region as fixed effects.</description>
        <time_frame>Pre-dose (0.0 h) and 12 h post dose at Week 4, 20, 40 min, 1, 1.5, 2.0, 2.5, 3.0, 4.0, 6.0, 8.0, 1-4, 8-12, and 24 h at Month 3, 6 and 12</time_frame>
        <population>Pharmacokinetic Parameters Population comprised of any participant in the pharmacokinetic concentration population who provided pharmacokinetic parameters. Only those participants available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Ronacaleret, 100 mg Tablet, OD</title>
            <description>Participants received ronacaleret, 100 mg tablet, OD and matching placebo, OW (matching to Alendronate capsule) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
          </group>
          <group group_id="O2">
            <title>Ronacaleret, 200 mg Tablet, OD</title>
            <description>Participants received ronacaleret, 200 mg tablet, OD and matching placebo, OW (matching to Alendronate capsule) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
          </group>
          <group group_id="O3">
            <title>Ronacaleret, 300 mg Tablet, OD</title>
            <description>Participants received ronacaleret, 300 mg tablet, OD and matching placebo, OW (matching to Alendronate capsule) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
          </group>
          <group group_id="O4">
            <title>Ronacaleret, 400 mg Tablet, OD</title>
            <description>Participants received Ronacaleret, 400 mg tablet, OD and matching placebo, OW (matching to Alendronate capsule) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-time Curve Over the Dosing Interval (AUC 0-t) and Area Under the Concentration-time Curve Over the Dosing Interval (AUC 0-tau) of Ronacaleret</title>
          <description>Blood samples were collected and analyzed for concentrations of ronacaleret. The individual blood concentration-time data from the intensive pharmacokinetic and pharmacodynamics subgroup of participants were analyzed by standard noncompartmental methods. Blood samples were collected and analyzed for concentrations of ronacaleret. The individual blood concentration-time data from the intensive PK-PD subgroup of participants were analyzed by standard noncompartmental methods. Following log transformation, AUC(0-t) and AUC(0-τ) of ronacaleret were separately analyzed by ANOVA using mixed effects model, fitting treatment and country/region as fixed effects.</description>
          <population>Pharmacokinetic Parameters Population comprised of any participant in the pharmacokinetic concentration population who provided pharmacokinetic parameters. Only those participants available at the specified time points were analyzed.</population>
          <units>nanogram*hour per millilitre (ng*hr/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUC 0-t, Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2495.8751" spread="53.13"/>
                    <measurement group_id="O2" value="4575.8746" spread="35.50"/>
                    <measurement group_id="O3" value="7545.3302" spread="42.26"/>
                    <measurement group_id="O4" value="6712.0537" spread="79.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC 0-t, Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2766.6822" spread="64.20"/>
                    <measurement group_id="O2" value="4548.6490" spread="43.87"/>
                    <measurement group_id="O3" value="9259.3127" spread="37.74"/>
                    <measurement group_id="O4" value="6798.4219" spread="65.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC 0-tau, Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3628.0901" spread="66.72"/>
                    <measurement group_id="O2" value="6428.5540" spread="36.62"/>
                    <measurement group_id="O3" value="10825.9083" spread="50.48"/>
                    <measurement group_id="O4" value="9810.4614" spread="80.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC 0-tau, Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3922.9369" spread="75.72"/>
                    <measurement group_id="O2" value="6455.1756" spread="42.03"/>
                    <measurement group_id="O3" value="14827.6940" spread="38.28"/>
                    <measurement group_id="O4" value="10079.2847" spread="71.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Blood Concentration (Cmax) of Ronacaleret</title>
        <description>Blood samples were collected and analyzed for concentrations of ronacaleret. The individual blood concentration-time data from the intensive pharmacokinetic and pharmacodynamics subgroup of participants were analyzed by standard noncompartmental methods. Blood samples were collected and analyzed for concentrations of ronacaleret. The individual blood concentration-time data from the intensive PK-PD subgroup of participants were analyzed by standard noncompartmental methods. Following log transformation, Cmax of ronacaleret were separately analyzed by ANOVA using mixed effects model, fitting treatment and country/region as fixed effects.</description>
        <time_frame>Pre-dose (0.0 h) and 12 h post dose at Week 4, 20, 40 min, 1, 1.5, 2.0, 2.5, 3.0, 4.0, 6.0, 8.0, 1-4, 8-12, and 24 h at Month 3, 6 and 12</time_frame>
        <population>Pharmacokinetic parameter population.</population>
        <group_list>
          <group group_id="O1">
            <title>Ronacaleret, 100 mg Tablet, OD</title>
            <description>Participants received ronacaleret, 100 mg tablet, OD and matching placebo, OW (matching to Alendronate capsule) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
          </group>
          <group group_id="O2">
            <title>Ronacaleret, 200 mg Tablet, OD</title>
            <description>Participants received ronacaleret, 200 mg tablet, OD and matching placebo, OW (matching to Alendronate capsule) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
          </group>
          <group group_id="O3">
            <title>Ronacaleret, 300 mg Tablet, OD</title>
            <description>Participants received ronacaleret, 300 mg tablet, OD and matching placebo, OW (matching to Alendronate capsule) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
          </group>
          <group group_id="O4">
            <title>Ronacaleret, 400 mg Tablet, OD</title>
            <description>Participants received Ronacaleret, 400 mg tablet, OD and matching placebo, OW (matching to Alendronate capsule) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Blood Concentration (Cmax) of Ronacaleret</title>
          <description>Blood samples were collected and analyzed for concentrations of ronacaleret. The individual blood concentration-time data from the intensive pharmacokinetic and pharmacodynamics subgroup of participants were analyzed by standard noncompartmental methods. Blood samples were collected and analyzed for concentrations of ronacaleret. The individual blood concentration-time data from the intensive PK-PD subgroup of participants were analyzed by standard noncompartmental methods. Following log transformation, Cmax of ronacaleret were separately analyzed by ANOVA using mixed effects model, fitting treatment and country/region as fixed effects.</description>
          <population>Pharmacokinetic parameter population.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cmax. Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="572.10" spread="44.79"/>
                    <measurement group_id="O2" value="1050.42" spread="40.82"/>
                    <measurement group_id="O3" value="1756.45" spread="52.80"/>
                    <measurement group_id="O4" value="1556.58" spread="76.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmax. Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="661.70" spread="74.39"/>
                    <measurement group_id="O2" value="999.91" spread="37.18"/>
                    <measurement group_id="O3" value="2254.26" spread="41.57"/>
                    <measurement group_id="O4" value="1506.45" spread="63.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time Required to Achieve Maximum Concentration of Ronacaleret in Blood (Tmax)</title>
        <description>Blood samples were collected and analyzed for concentrations of ronacaleret. The individual blood concentration-time data from the intensive pharmacokinetic and pharmacodynamics subgroup of participants were analyzed by standard noncompartmental methods.</description>
        <time_frame>Pre-dose (0.0 h) and 12 h post dose at Week 4, 20, 40 min, 1, 1.5, 2.0, 2.5, 3.0, 4.0, 6.0, 8.0, 1-4, 8-12, and 24 h at Month 3, 6 and 12</time_frame>
        <population>Pharmacokinetic parameters population. Only those participants available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Ronacaleret, 100 mg Tablet, OD</title>
            <description>Participants received ronacaleret, 100 mg tablet, OD and matching placebo, OW (matching to Alendronate capsule) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
          </group>
          <group group_id="O2">
            <title>Ronacaleret, 200 mg Tablet, OD</title>
            <description>Participants received ronacaleret, 200 mg tablet, OD and matching placebo, OW (matching to Alendronate capsule) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
          </group>
          <group group_id="O3">
            <title>Ronacaleret, 300 mg Tablet, OD</title>
            <description>Participants received ronacaleret, 300 mg tablet, OD and matching placebo, OW (matching to Alendronate capsule) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
          </group>
          <group group_id="O4">
            <title>Ronacaleret, 400 mg Tablet, OD</title>
            <description>Participants received Ronacaleret, 400 mg tablet, OD and matching placebo, OW (matching to Alendronate capsule) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Time Required to Achieve Maximum Concentration of Ronacaleret in Blood (Tmax)</title>
          <description>Blood samples were collected and analyzed for concentrations of ronacaleret. The individual blood concentration-time data from the intensive pharmacokinetic and pharmacodynamics subgroup of participants were analyzed by standard noncompartmental methods.</description>
          <population>Pharmacokinetic parameters population. Only those participants available at the specified time points were analyzed.</population>
          <units>h</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Tmax, Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.483" lower_limit="0.98" upper_limit="4.02"/>
                    <measurement group_id="O2" value="1.250" lower_limit="0.67" upper_limit="3.03"/>
                    <measurement group_id="O3" value="1.700" lower_limit="0.33" upper_limit="3.02"/>
                    <measurement group_id="O4" value="1.500" lower_limit="0.67" upper_limit="4.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tmax, Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.000" lower_limit="0.33" upper_limit="4.00"/>
                    <measurement group_id="O2" value="1.500" lower_limit="0.67" upper_limit="2.95"/>
                    <measurement group_id="O3" value="1.500" lower_limit="0.00" upper_limit="2.58"/>
                    <measurement group_id="O4" value="1.500" lower_limit="0.33" upper_limit="3.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to Follow-up visit (12 month and 2 weeks)</time_frame>
      <desc>Intent-to-Treat population was used to report AEs</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Participants received matching placebo OD (matching to ronacaleret tablet) and matching placebo OW (matching to Alendronate capsule) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
        </group>
        <group group_id="E2">
          <title>Ronacaleret, 100 mg Tablet, OD</title>
          <description>Participants received ronacaleret, 100 mg tablet, OD and matching placebo, OW (matching to Alendronate capsule) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
        </group>
        <group group_id="E3">
          <title>Ronacaleret, 200 mg Tablet, OD</title>
          <description>Participants received ronacaleret, 200 mg tablet, OD and matching placebo, OW (matching to Alendronate capsule) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
        </group>
        <group group_id="E4">
          <title>Ronacaleret, 300 mg Tablet, OD</title>
          <description>Participants received ronacaleret, 300 mg tablet, OD and matching placebo, OW (matching to Alendronate capsule) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
        </group>
        <group group_id="E5">
          <title>Ronacaleret, 400 mg Tablet, OD</title>
          <description>Participants received Ronacaleret, 400 mg tablet, OD and matching placebo, OW (matching to Alendronate capsule) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
        </group>
        <group group_id="E6">
          <title>Alendronate, 70 mg, Capsule, OW</title>
          <description>Participants received Alendronate, 70 mg, capsule, OW and matching placebo OD (matching to ronacaleret tablet) for 12 months. Participants were supplied with elemental calcium 500-660 mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
        </group>
        <group group_id="E7">
          <title>Teriparatide, 20 mcg, SC Injection, OD</title>
          <description>Participants received Teriparatide, 20 mcg, SC injection, OD for 12 months. Participants were supplied with elemental calcium 500-660mg and vitamin D, at least 400 IU, OD in the evening as dietary supplements throughout the study.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="88"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="87"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Atrioventricular block</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Pulmonary tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Nerve injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Smear cervix abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Metastatic malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Neuroma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Non-Hodgkin's lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Renal neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Cystocele</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nasal septum deviation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Salpingo-oophorectomy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="54" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="57" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="55" subjects_at_risk="88"/>
                <counts group_id="E5" subjects_affected="61" subjects_at_risk="87"/>
                <counts group_id="E6" subjects_affected="46" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="30" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="88"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="87"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="88"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="87"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="88"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="87"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="88"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="87"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="88"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="87"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="88"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="88"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="87"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="88"/>
                <counts group_id="E5" subjects_affected="16" subjects_at_risk="87"/>
                <counts group_id="E6" subjects_affected="12" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="88"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="87"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="88"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="87"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="88"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="87"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="87"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Tooth infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="88"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="88"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="87"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="88"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="87"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="88"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="87"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="87"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="88"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="88"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="87"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="88"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="87"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="88"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="87"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="87"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="82"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="88"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="87"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="89"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The study was terminated for futility in a phased manner by the sponsor on 25-Sep-2008 once the results of a planned 6-month interim analysis were available.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

